celecoxib has been researched along with dinoprostone in 390 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (1.28) | 18.2507 |
| 2000's | 220 (56.41) | 29.6817 |
| 2010's | 147 (37.69) | 24.3611 |
| 2020's | 18 (4.62) | 2.80 |
| Authors | Studies |
|---|---|
| Borst, P; de Haas, M; Kuil, A; Reid, G; van der Heijden, I; Wielinga, P; Wijnholds, J; Zelcer, N | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cao, Z; Hammock, BD; Hwang, SH; Lee, KS; Li, X; Morisseau, C; Wagner, K; Xu, J; Yang, J | 1 |
| Isakson, PC; Lipsky, PE | 1 |
| Isakson, PC; Koboldt, CM; Masferrer, JL; Muhammad, J; Seibert, K; Shaffer, A; Smith, CJ; Talley, JJ; Zhang, Y; Zweifel, BS | 1 |
| Catella-Lawson, F; FitzGerald, GA; Kapoor, S; Lawson, JA; Mardini, IA; McAdam, BF | 1 |
| Gierse, JK; Isakson, PC; Koboldt, CM; Seibert, K; Walker, MC | 1 |
| Conti, CJ; Fischer, SM; Gordon, GB; Kelloff, G; Lo, HH; Lubet, RA; Seibert, K | 1 |
| Asfaha, S; McKnight, W; Muscará, MN; Wallace, JL | 1 |
| Chemtob, S; Clyman, RI; Heymann, MA; Lin, E; Roman, C; Takahashi, Y; Tse, MM | 1 |
| Davis, JV; Linder, JD; Mönkemüller, KE; Wilcox, CM | 1 |
| Oberyszyn, TM; Parrett, ML; Ross, MS; Wilgus, TA | 1 |
| Boyce, BF; Langenbach, R; Morham, SG; O'Keefe, RJ; Puzas, EJ; Rosier, RN; Schwarz, EM; Xing, L; Young, DA; Zhang, X | 1 |
| Momma, K; Saito, S; Sakai, M; Sasaki, Y; Tanebe, K; Yoneda, S | 1 |
| Bräutigam, L; Euchenhofer, C; Geisslinger, G; Grösch, S; Niederberger, E; Schmidt, H; Schmidtko, A; Tegeder, I; Vetter, G | 1 |
| García Rodríguez, LA; Patrignani, P; Patrono, C | 1 |
| Felix, E; Kempen, EC; Madden, T; Newman, RA; Yang, P | 1 |
| Bucher, M; Castrop, H; Grobecker, HF; Höcherl, K; Ittner, KP; Kees, F; Kurtz, A; Wolf, K | 1 |
| Bräutigam, L; Geisslinger, G; Niederberger, E; Tegeder, I; Vetter, G | 1 |
| Bourdi, M; Brady, JN; George, JW; Marchick, MR; Pise-Masison, CA; Pohl, LR; Radonovich, MF; Reilly, TP | 1 |
| Koki, AT; Leahy, KM; Masferrer, JL; Ornberg, RL; Wang, Y; Zweifel, BS | 1 |
| Nervetti, A; Rioda, WT | 1 |
| Cabré, F; Campos, J; Entrena, A; Espinosa, A; Gallo, MA; García, L; Mauleón, D; Palomer, A; Pascual, J; Trujillo, MA | 1 |
| Chen, CS; Johnson, AJ; Kulp, SK; Lin, HP; Song, X; Tseng, PH; Yang, YT | 1 |
| Bol, DK; Dell, J; Fischer, SM; Ho, CP; Kiguchi, K; Klein, R; Muga, S; Pilz, B; Rowley, RB; Swerdel, M | 1 |
| Figueiredo-Pereira, ME; Jansen, M; Li, Z; Rockwell, P | 1 |
| Alarcón de la Lastra, C; Berenguer, B; Martín, MJ; Moreno, FJ | 1 |
| Black, HS; Gerguis, J; Guevara, A; Lewis, AT; Orengo, IF; Phillips, R | 1 |
| Kawamori, T; Wakabayashi, K | 1 |
| Angelucci, L; Casolini, P; Catalani, A; Zuena, AR | 1 |
| Brahim, JS; Dionne, RA; Khan, AA; Rowan, JS | 1 |
| Bolli, R; Kodani, E; Shinmura, K; Takano, H; Tang, XL; Xuan, YT | 1 |
| Davis, TW; Durham, WF; Horton, J; Levine, BD; Masferrer, JL; Salazar, VS; Trifan, OC; Zweifel, BS | 1 |
| Arakawa, T; Kanatsu, K; Kato, S; Ogawa, Y; Okayama, M; Takeuchi, K; Watanabe, T | 1 |
| Davis, TW; Masferrer, JL; Ornberg, RL; Zweifel, BS | 1 |
| Almer, G; Drachman, DB; Dykes-Hoberg, M; Frank, K; Przedborski, S; Rothstein, JD; Teismann, P | 1 |
| Kawai, S; Kusunoki, N; Yamazaki, R | 1 |
| Hollenberg, MD; MacNaughton, WK; Seymour, ML; Zaidi, NF | 1 |
| Liu, ZR; Luo, XW; Wu, GS; Wu, JH; Zou, SQ | 1 |
| Calixto, JB; Pinheiro, RM | 1 |
| Liu, ZR; Tang, ZH; Wang, JH; Wu, GS; Zou, SQ | 1 |
| Hashitani, S; Maeda, T; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M | 1 |
| Demetris, AJ; Han, C; Leng, J; Michalopoulos, GK; Wu, T | 1 |
| Koki, AT; Oberyszyn, TM; Rubal, PA; Wilgus, TA; Zweifel, BS | 1 |
| Cripe, TP; Dickens, DS | 1 |
| Battaglia, A; Ferrandina, G; Gessi, M; Lauriola, L; Legge, F; Navarra, P; Ranelletti, FO; Salutari, V; Scambia, G; Testa, AC; Tringali, G; Werner, U | 1 |
| Hayashi, N; Hori, M; Horimoto, M; Irie, T; Kakiuchi, Y; Kawai, N; Kawano, S; Kimura, A; Komori, M; Murata, H; Nishida, T; Sasaki, Y; Tsuji, S; Tsujii, M; Yasumaru, M | 1 |
| Heering, P; Heise, G; Schrör, K; Waldner, C | 1 |
| Baratelli, F; Dubinett, SM; Holmes, EC; Mao, JT; Roth, MD; Serio, KJ; Strieter, RM; Zhu, L | 1 |
| Marziniak, M; Schäfers, M; Sommer, C; Sorkin, LS; Yaksh, TL | 1 |
| Bai, AH; Hu, PJ; Leung, WK; Lin, HL; Sung, JJ; Tang, BD; Yu, J; Zeng, ZR | 1 |
| Chun, KS; Kim, SH; Song, YS; Surh, YJ | 1 |
| Davis, TW; Heuvelman, DM; Masferrer, JL; Mehta, PP; O'Neal, JM; Pagel, MD; Zweifel, BS | 1 |
| Bost, KL; Bowman, CC | 1 |
| Badawi, AF; Badr, MZ; Eldeen, MB; Liu, Y; Ross, EA | 1 |
| Demetris, AJ; Han, C; Leng, J; Wu, T | 2 |
| Ong, CN; Shen, HM; Shi, X; Won, YK | 1 |
| Alves, DL; Caliari, MV; Duarte, ID; Francischi, JN; Maltos, KL; Menezes, GB; Rocha, OA; Santos, JM | 1 |
| Liu, Z; Qiu, F; Wu, G; Zou, S | 1 |
| Adhami, VM; Fu, P; Gupta, S; Hafeli, UO; Lewin, JS; MacLennan, GT; Mukhtar, H; Subbarayan, M | 1 |
| Aw, J; Haas, S; Krum, H; Liew, D | 1 |
| Breza, TS; Oberyszyn, TM; Tober, KL; Wilgus, TA | 1 |
| Gately, S; Li, WW | 1 |
| Ayers, GD; Cohen, DS; Half, E; Hawk, ET; Levin, B; Lynch, PM; Morris, JS; Morrow, JD; Sinicrope, FA; Stephens, LC | 1 |
| Bachelot, T; Guastalla, JP; Ray-Coquard, I | 2 |
| Jain, NK; Kulkarni, SK; Patil, CS; Singh, VP | 1 |
| Chu, K; Han, SY; Jeong, SW; Jung, KH; Kim, M; Lee, ST; Roh, JK | 1 |
| Amrite, AC; Ayalasomayajula, SP; Kompella, UB | 1 |
| Corbett, JA; Ensor, NJ; Gibson, KA; Heitmeier, MR; Kelly, CB; Maziasz, TJ; Mullis, KG | 1 |
| Beer, DG; Chen, X; Giordano, TJ; Jin, Z; Lin, Y; Lubet, RA; Shih, WC; Sood, S; Wang, P; Wang, S; Wu, N; Yang, CS | 1 |
| Davis, DW; Ellis, LM; Khanbolooki, S; Lashinger, LM; McConkey, DJ; Nawrocki, S; Raut, CP; Xiong, H | 1 |
| Flynn, JT; Hewett, J; Koivunen, D; Sauter, ER; Schlatter, L | 1 |
| Cristofoletti, R; Fabricio, AS; Navarra, P; Souza, GE; Veiga, FH | 1 |
| Evans, DM; Sloan Stakleff, KD | 1 |
| Basu, GD; Gendler, SJ; Lagioia, M; Mukherjee, P; Pathangey, LB; Tinder, TL | 1 |
| Busse, R; Fleming, I; Kohlstedt, K | 1 |
| Narayanan, BA; Narayanan, NK; Pittman, B; Reddy, BS | 1 |
| Dong, XY; Lu, YM; Zhang, L | 1 |
| Bogolepova, AE; Shakhmatova, EI | 1 |
| Kitaoka, K; Kobayashi, T; Ogawa, Y; Seguchi, H; Taguchi, H; Takahashi, T; Tani, T; Uemura, Y; Yamamoto, H; Yoshida, S | 1 |
| Bjorling, DE; Calamon-Dixon, JL; Jerde, TJ; Nakada, SY | 1 |
| Carey, RI; Dandekar, DS; Lokeshwar, BL; Lopez, M | 1 |
| Duffy, DM; Seachord, CL; VandeVoort, CA | 1 |
| Arroyo, V; Clària, J; Escolar, G; Ginès, P; Jiménez, W; Kent, JD; López-Parra, M; Ruiz-Del-Arbol, L; Vucelic, B | 1 |
| Atilla, G; Baylas, H; Berdeli, AH; Buduneli, E; Buduneli, N; Vardar, S | 1 |
| Chen, TC; Hofman, FM; Kardosh, A; Petasis, NA; Schönthal, AH; Uddin, J; Wang, W | 1 |
| Kohn, EC; Liotta, LA; Mehta, AI; Petricoin, EF; Winters, ME | 1 |
| Handa, H; Ito, T; Kawai, S; Kusunoki, N; Sakurai, N; Suguro, T | 1 |
| Jang, JH; Surh, YJ | 1 |
| Bijlsma, JW; Lafeber, FP; Mastbergen, SC | 2 |
| Altorki, NK; Dannenberg, AJ; Duffield-Lillico, AJ; Golijanin, D; Port, JL; Subbaramaiah, K; Thaler, HT; Zhang, F | 1 |
| Di, F; Li, X; Wu, G; Yi, J; Zou, S | 1 |
| Gregor, JI; Heukamp, I; Jacobi, CA; Kiewert, C; Kilian, M; Kristiansen, G; Schimke, I; Walz, MK; Wenger, FA | 1 |
| Aimbire, F; Albertine, R; Castro-Faria-Neto, HC; Chavantes, MC; de Magalhães, RG; Lopes-Martins, RA; Pacheco, MT; Zângaro, RA | 1 |
| Siddiqui, A; Waris, G | 1 |
| Huang, Y; Liu, J; Wang, LZ; Zhang, WY; Zhu, XZ | 1 |
| Chatterjee, A; Jackson, T; Shaik, MS; Singh, M | 1 |
| Fukunaga, M; Hayashi, A; Kimoto, A; Kobayashi, S; Miyata, K; Noguchi, M; Sasamata, M; Yoshino, T | 1 |
| Fujimori, S; Futagami, S; Gudis, K; Kishida, T; Mitsui, K; Nagata, K; Sakamoto, C; Seo, T; Tanaka, S; Tatsuguchi, A; Tsukui, T; Wada, K; Yonezawa, M | 1 |
| Fujimura, T; Miwa, K; Oyama, K | 1 |
| Altundag, K; Altundag, O; Boruban, C; Silay, YS | 1 |
| Gautam, P; Poonam, D; Vinay, CS | 1 |
| Abramson, AL; Dannenberg, AJ; Shikowitz, MJ; Steinberg, BM; Wu, R | 1 |
| Carbone, DP; Csiki, I; Dang, T; Johnson, DH; Morrow, JD; Oates, J; Sandler, A; Shyr, Y; Williams, MK | 1 |
| Li, MH; Shen, JK; Yin, LL; Zhang, WY; Zhu, XZ | 1 |
| Beales, IL; Ogunwobi, OO | 1 |
| Kang, HK; Lee, E; Lim, SJ; Pyo, H | 1 |
| Bani, D; Capaccioli, S; Cianchi, F; Cortesini, C; Fabbroni, V; Fanti, E; Magnelli, L; Masini, E; Messerini, L; Perigli, G; Perna, F; Schiavone, N | 1 |
| Arakawa, T; Fujiwara, Y; Hamaguchi, M; Hayakawa, T; Higuchi, K; Okuyama, M; Oshitani, N; Sasaki, E; Sugawa, T; Tominaga, K; Watanabe, T | 1 |
| Frölich, JC; Gutzki, FM; Marhauer, V; Stichtenoth, DO; Tsikas, D | 1 |
| Ferrario, A; Fisher, AM; Gomer, CJ; Rucker, N | 1 |
| Jun, HJ; Kim, GE; Kim, HS; Park, JS; Pyo, H; Shin, YK; Suh, CO; Yun, YS | 1 |
| Arber, N; Caspi, D; Elkayam, O; Kazanov, D; Lev-Ari, S; Lichtenberg, D; Strier, L | 1 |
| Chiba, T; Fukui, H; Kanda, N; Kawada, M; Konda, Y; Nakajima, T; Sawabu, T; Seno, H; Takeuchi, T; Uenoyoma, Y | 1 |
| Han, AR; Jeong, YH; Kim, MS; Lee, SK; Seo, EK | 1 |
| Bijlsma, JW; Lafeber, FP; Marijnissen, AC; Mastbergen, SC; van Roermund, PM; Vianen, ME; Zoer, B | 1 |
| Lin, GC; Liu, ZG; Lu, ZH; Mei, QB; Meng, JR; Shi, YX; Xiong, XY; Zhang, BL; Zhou, YM | 1 |
| Cui, W; Hu, KQ; Yu, CH | 1 |
| Bai, F; Chen, Y; Du, Y; Fan, D; Han, S; Liang, J; Lin, T; Wang, J; Wu, K; Xie, H; Zhai, H | 1 |
| Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
| Arber, N; Benamouzig, R; Birkenfeld, S; Cohen-Noyman, E; Dvory-Sobol, H; Figer, A; Kazanov, D; Madar-Shapiro, L | 1 |
| Matsuda, K; Matsushita, T; Nakamura, S | 1 |
| Alvarez-Soria, MA; Calvo, E; Egido, J; Hernández, M; Herrero-Beaumont, G; Largo, R; Sánchez-Pernaute, O; Santillana, J | 1 |
| Arolt, V; Cerovecki, A; Dehning, S; Douhe, A; Goldstein-Müller, B; Hetzel, G; Kleindienst, N; Maino, K; Möller, HJ; Müller, N; Riedel, M; Schwarz, MJ; Spellmann, I | 1 |
| Amrite, AC; Ayalasomayajula, SP; Cheruvu, NP; Kompella, UB | 1 |
| Gitlin, JM; King, VL; Loftin, CD; Trivedi, DB | 1 |
| Fujita, I; Hizue, M; Kanai, Y; Matsuura, T; Murase, A; Murata, Y; Naganeo, R; Nakao, K; Okumura, T; Sakakibara, A | 1 |
| Brogi, E; Dannenberg, AJ; Fishman, J; Hla, T; Howe, LR; Hudis, C; Liu, CH; Port, ER; Subbaramaiah, K | 1 |
| Bertagnolli, MM; Carothers, AM; Cho, NL; Moran, AE; Redston, M | 1 |
| Andreasson, KI; Cudkowicz, ME; Drachman, DB; Rothstein, JD; Schoenfeld, DA; Shefner, JM; Zhang, H | 1 |
| Dong, Z; Wang, MH; Yang, T; Zhang, A | 1 |
| Chatterjee, A; Fulzele, SV; Jackson, T; Shaik, MS; Singh, M | 1 |
| Barreto-de-Souza, V; Bou-Habib, DC; Bozza, PT; Castro-Faria-Neto, HC; Lima, RG; Moreira, L; Paes-Leme, J | 1 |
| Antunes, E; Camargo, EA; De Nucci, G; Desouza, IA; Franco-Penteado, CF; Lima, CS; Muscará, MN; Teixeira, SA | 1 |
| Barreto-de-Souza, V; Bou-Habib, DC; Bozza, PT; Castro-Faria-Neto, HC; Pacheco, GJ; Saraiva, EM; Silva, AR | 1 |
| Flynn, JT; Hewett, JE; Qin, W; Sauter, ER; Schlatter, L | 1 |
| Hu, PJ; Tang, BD; Zeng, ZR | 1 |
| de Francischi, JN; de Menezes, GB; dos Reis, WG; Duarte, ID; Santos, JM | 1 |
| Chono, K; Funatsu, T; Hirata, T; Keto, Y; Kimoto, A; Sasamata, M | 1 |
| Bechi, P; Capaccioli, S; Cianchi, F; Cortesini, C; Fabbroni, V; Fanti, E; Lulli, M; Magnelli, L; Masini, E; Messerini, L; Papucci, L; Perigli, G; Perna, F; Schiavone, N; Vannacci, A | 1 |
| Chan, HL; Chan, KK; Cheng, AS; Cheung, KF; Ching, AK; Chu, ES; Chui, YL; Go, MY; Hui, AY; Leung, WK; Sung, JJ; Yu, J | 1 |
| Almuete, V; Amador, ML; Chan, A; Danenberg, K; Hidalgo, M; Hruban, RH; Jimeno, A; Kulesza, P; Kuramochi, H; Maitra, A; Messersmith, WA; Rubio-Viqueira, B; Tanaka, K; Wang, X; Wheelhouse, J; Yeo, CJ; Zhang, X | 1 |
| Geisslinger, G; Grundei, I; Lötsch, J; Reus, M; Schmidt, R; Schuss, P; Skarke, C | 1 |
| Dittmann, K; Kehlbach, R; Krebiehl, G; Ohneseit, PA; Rodemann, HP | 1 |
| Becker, TL; Gambero, A; Maróstica, M; Pedrazzoli, J | 1 |
| Cheah, ES; Kang, KB; Moore, XL; Wang, TT; Wong, MC; Woon, CT; Zhu, C | 1 |
| Dial, EJ; Lichtenberger, LM; Romero, JJ | 1 |
| Arber, N; Ben-Yosef, R; Kazanov, D; Lev-Ari, S; Liberman, E | 1 |
| Cai, KQ; Hamilton, TC; Klein-Szanto, A; Smedberg, JL; Smith, ER; Xu, XX; Yang, WL | 1 |
| Cho, SJ; Jung, HC; Kim, JS; Kim, N; Song, IS | 1 |
| Aoi, Y; Hayashi, S; Kato, S; Nishio, H; Okayama, M; Takeuchi, K | 1 |
| Lotan, R; Newman, RA; Schroeder, CP; Yang, P | 1 |
| Barden, CA; Chandler, HL; Colitz, CM; Kusewitt, DF; Lu, P | 1 |
| Kosaki, N; Matsumoto, H; Miyamoto, T; Niki, Y; Tada, N; Takaishi, H; Takito, J; Toyama, Y | 1 |
| Cmiel, A; Gawlewicz-Mroczka, A; Gielicz, A; Mastalerz, L; Sanak, M; Szczeklik, A | 1 |
| Machado, RR; Proudfoot, AE; Soares, DM; Souza, GE | 1 |
| Bartholomeusz, C; Sugimoto, T; Tari, AM; Ueno, NT | 1 |
| Wadman, M | 1 |
| Bi, Q; Bolli, R; Dai, S; Rokosh, GD; Sato, H; Shirk, G; Tang, XL | 1 |
| Kita, Y; Murata, Y; Okumura, T; Sakakibara, A | 1 |
| Choe, M; Choi, EM; Ha, KS; Han, JA; Kim, H; Kim, JI; Kim, SR; Kim, SS; Kim, YM; Lee, EJ; Park, JH | 1 |
| Farooqui, M; Griffin, RJ; Gupta, K; Li, Y; Poonawala, T; Rogers, T; Song, CW | 1 |
| Andratschke, NH; Dittmann, KH; Mayer, C; Milas, L; Ohneseit, PA; Raju, U; Rodemann, HP | 1 |
| Akiyoshi, M; Hiramitsu, T; Ito, H; Kitaori, T; Nakamura, T; Nishitani, K; Tsutsumi, R; Yasuda, T | 1 |
| Adams, JA; Aria, J; Bassuk, J; Kurlansky, P; Lamas, GA; Lozano, H; Wu, D | 1 |
| Anilkumar, K; Aparna, A; Arunasree, KM; Reddanna, P; Reddy, GV; Roy, KR | 1 |
| Davies, BR; Dovedi, SJ; Kelly, JD; Kirby, JA; Leung, H | 1 |
| Brandau, S | 1 |
| Batu, OS; Erol, K | 1 |
| de Boeck, G; de Bruijn, EA; de Heer, P; Guertens, G; Junggeburt, JM; Koudijs, MM; Kuppen, PJ; Nagelkerke, JF; Sandel, MH; van de Velde, CJ | 1 |
| Bohrer, D; Castelli, M; Cavalheiro, EA; Ferreira, J; Fighera, MR; Fiorenza, NG; Furian, AF; Machado, P; Mello, CF; Oliveira, MS; Royes, LF; Veiga, M | 1 |
| Chen, YC; Flynn, JT; Hewett, JE; Qin, W; Rottinghaus, G; Ruhlen, RL; Sauter, ER | 1 |
| Arber, N; Lev-Ari, S; Lichtenberg, D | 1 |
| Jin, UH; Kim, CH; Kim, KS; Kwon, DY; Park, SD; Suh, SJ | 1 |
| Chen, J; Du, DP; Ji, Y; Jiang, W; Ma, K; Zhou, QH | 1 |
| Dhawan, D; Jeffreys, AB; Knapp, DW; Stewart, JC; Zheng, R | 1 |
| Harris, DT; Sakiestewa, D; Titone, D; Witten, M | 1 |
| Cavanaugh, PF; Chappell, DL; Dallob, AL; Flynn, ME; Hilliard, DA; Larson, PJ; Laterza, OF; Miller, J; Royalty, J; Schwartz, JI; Snyder, KM; Wagner, JA | 1 |
| Bai, X; Chen, W; He, Y; Wang, L; Xie, X | 1 |
| Chai, N; Chen, C; Fan, D; Feitelson, MA; Gao, L; Liu, J; Pan, Y; Song, J; Song, Z; Sun, S; Wang, J; Wu, K; Xie, H; Zhao, L | 1 |
| Hedger, MP; Hirst, JJ; Liew, S; Meachem, SJ; Muir, JA; Winnall, WR | 1 |
| Angioni, C; Corban-Wilhelm, H; Geisslinger, G; Grösch, S; Janssen, A; Maier, TJ; Schiffmann, S; Wobst, I | 1 |
| Alvarez-Soria, MA; Calvo, E; Egido, J; Herrero-Beaumont, G; Largo, R; Moreno-Rubio, J; Santillana, J | 1 |
| Heng, CK; Zhao, Y; Zhou, S | 1 |
| Ahmad, A; Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
| Buyse, M; Farinotti, R; Zrieki, A | 1 |
| Colby, JK; Conti, CJ; Fischer, SM; Kawamoto, T; Kiguchi, K; Klein, RD; McArthur, MJ; Pavone, AI; Riggs, PK; Sawicki, J | 1 |
| Machado, RR; Melo, MC; Soares, DM; Souza, GE; Yamashiro, LH | 1 |
| Bilotas, M; Borghi, M; Buquet, R; Meresman, G; Olivares, C; Sueldo, C; Tesone, M | 1 |
| Liu, Q; Mao-Ying, QL; Mi, WL; Wang, XW; Wang, YQ; Wu, GC | 1 |
| Crooks, PA; Holcomb, B; Neelakantan, S; Njoku, V; Ralstin, M; Schmidt, CM; Sweeney, CJ; Wu, H; Yip-Schneider, MT | 1 |
| Baek, YH; Choi, DY; Huh, JE; Kim, YJ; Lee, JD; Park, DS | 1 |
| Ahn, DW; Cho, SJ; Jung, HC; Kim, CH; Kim, JS; Kim, N; Lee, KS; Lee, MK; Park, JH; Song, IS | 1 |
| Chen, YC; Flynn, JT; Hewett, JE; Kliethermes, B; Mannello, F; Qin, W; Rottinghaus, G; Sauter, ER; Zhu, W | 1 |
| Bijlsma, JW; de Boer, TN; Huisman, AM; Lafeber, FJ; Mastbergen, SC; Niehoff, AG; Polak, AA; Saris, D; van Rinsum, AC | 1 |
| Gitlin, JM; Loftin, CD | 1 |
| Katono, T; Kawato, T; Kitami, S; Maeno, M; Morita, T; Motohashi, M; Suzuki, N; Tanabe, N; Tanaka, H | 1 |
| Li, X; Liu, H; Wei, W | 1 |
| Manku, M; Song, C; Zhang, XY | 1 |
| Esumi, LA; Gomes, VL; Hipolide, DC; Nobrega, JN; Palma, BD; Seabra, ML; Tufik, S | 1 |
| Bertagnolli, MM; Dorfman, DM; Goguen, L; Haddad, RI; Krane, JF; Li, Y; Moran, AE; Norris, CM; Othus, M; Posner, MR; Wirth, LJ | 1 |
| Aguiar, FA; de Souza, GE; do Vale, ML; Kanashiro, A; Machado, RR; Malvar, Ddo C; Pessini, AC; Soares, DM | 1 |
| Al-Asmar, B; Chidiac, JJ; Jabbur, SJ; Rifai, K; Saadé, NE | 1 |
| Cohen, R; Jullienne, A; Lausson, S; Lepoivre, M; Quidville, V; Segond, N; Tebbi, A | 1 |
| Ding, YQ; Li, WZ; Wang, XY | 1 |
| Choi, HK; Hur, GY; In, KH; Jung, JY; Jung, KH; Kang, KH; Kim, JH; Lee, KJ; Lee, SY; Shim, JJ; Shin, C; Yoo, SH | 1 |
| Itadani, H; Kotani, H; Oshima, H; Oshima, M; Taketo, MM | 1 |
| Baek, SJ; Chrysovergis, K; Eling, TE; Iguchi, G; Langenbach, R; Lee, SH | 1 |
| Sharma, P; Suresh, S | 1 |
| Arai, I; Futaki, N; Harada, M; Hashimoto, Y; Honma, Y; Hoshi, K; Nakaike, S; Sugimoto, M | 1 |
| Aida, Y; Honda, K; Maeno, M; Matsumura, H; Namba, A; Shimizu, O; Suzuki, N; Tanabe, N; Watanabe, Y | 1 |
| Akhondzadeh, S; Ghoreishi, A; Jafari, S; Kamalipour, A; Mohebbi-Rasa, S; Nasehi, AA; Raisi, F; Raznahan, M; Salehi, B | 1 |
| Benestad, HB; Drange, M; Egner, IM; Fjeld, JG; Hallén, J; Langberg, H; Paulsen, G; Raastad, T | 1 |
| Cho, KH; Kim, JY; Kim, YM; Lee, EJ; Park, SY; Pyo, H | 1 |
| Oberyszyn, TM; Schick, JS; Thomas-Ahner, JM; Wulff, BC | 1 |
| Baek, YH; Huh, JE; Park, DS | 1 |
| Li, J; Liu, LH; Sang, MX; Shan, BE; Wang, L; Zhang, C | 1 |
| Kaneshiro, T; Kawamori, T; Maalouf, S; Maruyama, T; Okumura, M; Uflacker, A | 1 |
| Liu, H; Liu, Y; Lv, Y; Xiao, J; Yang, H; Yang, Y; Zhao, L | 2 |
| Guruswamy, S; Kopelovich, L; Patlolla, JM; Rao, CV; Steele, VE; Swamy, MV | 1 |
| Chen, X; Li, GD; Ou-Yang, Q; Wang, RH; Xiang, JY | 1 |
| Bingaman, DP; Clark, ML; Penn, JS; Yang, R; Yanni, SE | 1 |
| Cary, L; Elliott, TB; Jiao, W; Kiang, JG; Ledney, GD; Pellmar, TC | 1 |
| de Leng, WW; Leguit, RJ; Maciejewski, R; Milne, AN; Morsink, FH; Offerhaus, GJ; Polkowski, WP; Sitarz, R | 1 |
| Koyama, Y; Kuwabara, A; Maeno, M; Mitsui, N; Sanuki, R; Shimizu, N; Shionome, C; Suzuki, N; Zhang, F | 1 |
| Buttars, S; Done, SJ; Tran-Thanh, D; Wen, Y; Wilson, C | 1 |
| Alvarez-Soria, MA; Herrero-Beaumont, G; Largo, R; Moreno-Rubio, J; Tardio, L | 1 |
| Conlon, KC; Geary, M; Manahan, E; McKeown, C; McMillan, H; Murphy, JF; Rogers, A; Toomey, DP | 1 |
| Aida, Y; Honda, K; Maeno, M; Matsumura, H; Namba, A; Suzuki, N; Tanaka, H; Watanabe, Y | 1 |
| Aronoff, DM; Carlos, D; Faccioli, LH; Lourenço, EV; Machado, ER; Ramos, SG; Silva, EV; Sorgi, CA; Souza, GE; Ueta, MT | 1 |
| Bjarnason, IT; Hotz-Behofsits, C; Simpson, RJ; Walley, M | 1 |
| Cho, YJ; Huh, JW; Hwang, YS; Jeon, BT; Kim, HJ; Kim, JH; Lee, JD; Lee, JH; Lee, SD; Nizamudtinova, IT; Oh, YM; Roh, GS; Yi, CO | 1 |
| Fang, JF; Guo, WP; Liu, JP; Wei, HB; Zheng, ZH | 2 |
| Califano, JA; Fang, Y; Gu, X; Guo, Y; Hao, Y; Ji, H; Pang, X; Sha, W; Southerland, WM; Zhao, Y; Zhou, Y | 1 |
| Hashitani, S; Kishimoto, H; Noguchi, K; Ohtsu, N; Segawa, E; Takaoka, K; Urade, M | 1 |
| Frank, PG; Lanza-Jacoby, S; Laury-Kleintop, L; Raval, M; Yan, G | 1 |
| Ferrario, A; Gomer, CJ | 1 |
| Kimura, A; Koyama, Y; Maeno, M; Mitsui, N; Nakajima, A; Sanuki, R; Shimizu, N; Suzuki, N; Zhang, F | 1 |
| Chen, L; Lv, X; Xiang, D; Xu, Z; Zhang, M; Zhang, X | 1 |
| Case, N; Rubin, J; Sen, B; Styner, M; Xie, Z | 1 |
| Cecchini, R; Cunha, NV; de Abreu, SB; Grassiolli, S; Guarnier, FA; Martins-Pinge, MC; Mazzuco, TL; Panis, C; Pinge-Filho, P | 1 |
| Bakhle, YS; Camêlo, VM; de Francischi, JN; Dos Reis, WG; Paiva-Lima, P; Rezende, RM | 1 |
| Huo, QJ; Li, WZ; Wang, XY; Xu, F | 1 |
| Aerts, JG; Hegmans, JP; Hendriks, RW; Hoogsteden, HC; Lambers, ME; van Nimwegen, M; Veltman, JD | 1 |
| Aoyagi, T; Jia, Z; Liu, H; Wang, H; Wang, N; Yang, T | 1 |
| Isokawa, K; Kawato, T; Kitami, S; Maeno, M; Motohashi, M; Nakai, K; Ochiai, K; Suzuki, N; Tanaka, H; Wang, CL; Zhang, F | 1 |
| Hioki, K; Ishikawa, TO; Oguma, K; Oshima, H; Oshima, M; Popivanova, BK; Van Rooijen, N | 1 |
| Gao, PP; Li, J; Liu, FX; Wang, J; Wang, WH | 1 |
| Broadley, KJ; Clark, SR; Evans, RL; Gallimore, AM; Godkin, AJ; Hindley, JP; Jones, SA; Kidd, EJ; Lauder, SN; Leach, H; O'Donnell, V; Smart, K; Taylor, PR; Wise, MP | 1 |
| Alitalo, K; Hayashi, I; Hosono, K; Majima, M; Narumiya, S; Sakagami, H; Suzuki, T; Tamaki, H | 1 |
| Decker, SA; Fellows-Mayle, W; Fujita, M; Hamilton, RL; Kohanbash, G; Komohara, Y; Ohlfest, JR; Okada, H | 1 |
| Boshra, V; El Wakeel, GA; Nader, MA | 1 |
| Fomenko, IS; Panasyuk, NB; Sklyarov, AY | 1 |
| Brzozowski, T; Konturek, SJ; Kwiecien, S; Mazurkiewicz-Janik, M; Pajdo, R; Pawlik, M; Pawlik, WW; Ptak-Belowska, A; Sliwowski, Z | 1 |
| Dreicer, R; Elson, P; Finke, JH; Garcia, JA; Ireland, J; Rini, BI; Schwandt, A; Triozzi, P; Wyckhouse, J; Zhou, M | 1 |
| Feng, Y; Wang, M; Wang, Y; Xing, ZM; Yang, BX; Yu, LS; Zhao, H | 1 |
| Chen, L; Li, O; Li, W; Li, ZJ; Shao, D; Shi, Z; Wang, KZ; Xu, ZG; Zhang, M | 1 |
| Bosetti, F; Palumbo, S; Parente, L; Toscano, CD; Weigert, R | 1 |
| Lee, YK; Park, OJ | 1 |
| Cerella, C; Dicato, M; Diederich, M; Sobolewski, C | 1 |
| Chen, L; Geng, DC; Mao, HQ; Meng, B; Xu, YZ; Yang, HL; Zhu, XS | 1 |
| Baryawno, N; Darabi, A; FuskevÅg, OM; Johnsen, JI; Khan, Z; Kogner, P; Nordenskjöld, M; Odeberg, J; Rahbar, A; Segerström, L; Siesjö, P; Söderberg-Nauclér, C; Sveinbjörnsson, B; Taher, C; Wolmer-Solberg, N | 1 |
| Deckmann, K; Geisslinger, G; Grösch, S; Rörsch, F | 1 |
| Calvello, R; Carbone, ML; Cianciulli, A; Malerba, P; Panaro, MA; Perrone, MG; Scilimati, A; Vitale, P | 1 |
| Katiyar, SK; Singh, T | 1 |
| Edwards, RP; Kalinski, P; Muthuswamy, R; Obermajer, N; Odunsi, K | 1 |
| Banderó, CR; Bortoluzzi, VT; Bueno, LM; Gomes, AT; Jesse, AC; Mello, CF; Oliveira, MS; Rambo, LM; Salvadori, MG | 1 |
| Halmos, B; Li, G; Merchan, JR; Wang, A; Wang, X; Zhang, Z | 1 |
| Avril, S; Bronger, H; Cerny, C; Kiechle, M; Kraeft, S; Schmitt, M; Schwarz-Boeger, U; Stöckel, A | 1 |
| Andersson, M; Lönnroth, C; Lundholm, K; Nordgren, S | 1 |
| Chyczewski, L; Kowalczuk, O; Kuć, P; Laudański, P; Laudański, T | 1 |
| Bandyopadhyay, SK; Chatterjee, A; Chatterjee, S; Chattopadhyay, S; Das, S; Saha, A | 1 |
| Abdullah, RA; Dewey, WL; Li, C; Li, PL; Lichtman, AH; Poklis, JL; Ritter, JK; Xia, M | 1 |
| Aizman, E; Kloog, Y; Mor, A | 1 |
| Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM | 1 |
| Eberle, J; Fecker, LF; Rodust, PM; Stockfleth, E | 1 |
| Fujimura, T; Fushida, S; Hayashi, H; Kitagawa, H; Nagai, N; Ninomiya, I; Ohta, T; Oyama, K; Tajima, H | 1 |
| Al-Wadei, HA; Al-Wadei, MH; Schuller, HM; Ullah, MF | 1 |
| de Melo, MC; Figueiredo, MJ; Longhi-Balbinot, DT; Malvar, Ddo C; Martins, JM; Rae, GA; Soares, DM; Souza, GE | 1 |
| Akiba, Y; Amagase, K; Ebara, S; Satoh, H; Takeuchi, K | 1 |
| Barsic, M; Cetin, S; Dohar, JE; Hebda, PA; Lin, Y; Sandulache, VC; Tobey, AB; Yang, T | 1 |
| Furuya, H; Hannun, YA; Kawamori, T; Obeid, LM; Shimizu, Y; Wada, M; Yamada, PM | 1 |
| Chen, M; Gu, C; Liu, S; Wu, S; Yu, L; Zhong, D | 1 |
| Piplani, H; Rana, C; Sanyal, SN; Vaish, V | 1 |
| Akutsu, M; Ito, K; Kawashima, M; Kondoh, T; Ogura, N | 1 |
| Caderni, G; Dolara, P; Femia, AP; Salvadori, M | 1 |
| Gao, X; Li, M; Li, Y; Li, Z; Liu, L; Ma, X; Sang, Y; Shen, G; Wang, F; Wei, Y; Zhang, B; Zhao, J | 1 |
| Amanzadeh, A; Aslani, HR; Bidgoli, SA; Esfahani, M; Esfandiary, M; Ghahremani, MH; Habibzadeh, N; Salimi, M; Sedaghati, B | 1 |
| Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M | 1 |
| Amin, AR; Dave, M | 1 |
| Asmawidjaja, PS; Davelaar, N; Hazes, JM; Lubberts, E; Paulissen, SM; van Hamburg, JP | 1 |
| Bhattacharya, A; Li, Y; Shi, Y; Zhang, Y | 1 |
| Holick, MF; Jensen, M; Qin, W; Sauter, ER; Smith, C | 1 |
| Huwiler, A; Koch, A; Meyer Zu Heringdorf, D; Pfeilschifter, J; Völzke, A | 1 |
| Castle, SL; Fernandez, GE; Ford, HR; Grishin, AV; Papillon, SC; Pontarelli, EM; Short, SS; Smiley, N; Wang, J; Zobel, M | 1 |
| Cai, Y; Chen, S; Feng, X; Gao, S; Huang, X; Li, H; Li, Q; Liu, P; Liu, Z; Lu, J; Ye, J | 1 |
| Tang, G; Tian, M; Wang, Y; Xiu, C; Zhang, H | 1 |
| Bullins, KW; Denham, JW; Hanley, AV; Hanley, GA; Harirforoosh, S; Panus, PC; Wood, RC; Wyatt, JE | 1 |
| Da, L; Feng, D; Jiang, F; Li, M; Xu, L; Yang, X; Yin, R; Zhang, S; Zhang, Z | 1 |
| Kim, YG; Núñez, G; Shibuya, A; Totsuka, N; Udayanga, KG; Weinberg, JB | 1 |
| Dubinett, SM; Elashoff, D; Garon, EB; Grogan, T; Krysan, K; Kusko, R; Lenburg, ME; O'Hearn, J; Reckamp, KL; Sharma, S; Spira, AE; Walser, TC | 1 |
| Gao, C; Goh, JY; Ng, LY; Peck, Y; Wang, DA | 1 |
| Bresson-Bepoldin, L; Caulet-Maugendre, S; Gallouet, AS; Guillaudeux, T; Guilloton, F; Lamy, T; Pangault, C; Tarte, K; Travert, M | 1 |
| Shu, HK; Wang, L; Xu, K | 1 |
| Chan, HH; Cheng, KH; Chu, TH; Hsu, PI; Hu, TH; Kung, ML; Kuo, HM; Lai, KH; Lin, SW; Liu, LF; Ma, YL; Sun, CK; Tai, MH; Wang, EM; Wen, ZH | 1 |
| Ahmed, SB; Beaudin, AE; Hanly, PJ; Nicholl, DD; Poulin, MJ; Pun, M; Slater, DM; Steinback, CD; Wynne-Edwards, KE; Yang, C | 1 |
| Chang, JY; Chang, QY; Chu, R; Dai, KH; Duan, ZJ; Li, YL; Liu, Z; Mo, GQ; Zhang, ZF | 1 |
| Betts, CB; Borges, VF; Guo, Q; Jindal, S; Kapoor, P; Lyons, TR; Martinson, HA; Schedin, P | 1 |
| Brosh, T; Chechik, O; Dolkart, O; Gabet, Y; Liron, T; Maman, E; Somjen, D | 1 |
| Guo, XZ; Lin, H; Ren, LN; Shao, XD | 1 |
| Amano, H; Eshima, K; Hosono, K; Ito, Y; Iwabuchi, K; Iyoda, A; Kitasato, H; Kumagai, Y; Majima, M; Matsui, Y; Narumiya, S; Ogawa, F; Satoh, Y | 1 |
| Li, M; Tan, SY; Wang, XF | 1 |
| Jing, H; Li, Y; Ma, C; Qian, D; Qian, M; Zhou, Y | 1 |
| Han, M; Jiang, M; Li, S; Liu, S; Peng, Y; Zhang, P; Zhao, Q | 1 |
| Chan, KS; Chen, F; Ho, PL; Krasnow, R; Kurtova, AV; Lay, E; Lerner, SP; Mo, Q; Pazhanisamy, S; Roh, TT; Xiao, J | 1 |
| Barnholtz-Sloan, JS; Chen, Y; Dawson, DM; Fink, SP; Kopelovich, L; Kresak, A; Lawrence, EG; Markowitz, SD; Willis, JE; Yang, P; Zhang, Y | 1 |
| Cao, J; Li, WT; Lv, SJ; Yang, X; Zhao, CL | 1 |
| Bastos-Pereira, AL; Fraga, D; Leite, MC; Zampronio, AR | 1 |
| Bi, Y; Han, M; Jiang, M; Li, S; Xu, J; Xu, X | 1 |
| Meschede, AK; Schebb, NH; Willenberg, I | 1 |
| Chen, JH; Dominguez, CX; Kaech, SM; Parish, IA; Perry, CJ; Rosenberg, DW; Staron, MM; Tsui, YC | 1 |
| Chen, D; Fu, C; Gao, F; Hu, Q; Ren, H; Wang, G; Wang, H; Xia, Q; Yang, H; Ying, Z; Zhen, X; Zheng, L | 1 |
| Chen, H; Chen, L; Cheng, B; Jiang, C | 1 |
| Ito, K; Langelaan, M; Papen-Botterhuis, N; Potier, E; van Dijk, B; van DIjk, M | 1 |
| Cristea, MC; Dowell, JE; Dubinett, SM; Elashoff, RM; Figlin, RA; Fishbein, MC; Gardner, BK; Koczywas, M; Milne, GL; Reckamp, KL; Wang, HJ | 1 |
| Craenmehr, EG; Creemers, LB; Dhert, WJ; Grinwis, GC; Kranenburg, HJ; Langelaan, ML; Meij, BP; Papen-Botterhuis, NE; Plomp, SG; Riemers, FM; Tellegen, AR; Tryfonidou, MA; Willems, N; Yang, HY | 1 |
| Ackermann, BL; Campanale, KM; Dean, R; Hu, L; Huffman, LG; Jin, Y; Landschulz, W; McNearney, TA; Regev, A; Smith, CL; Stoltz, R; Yang, XY | 1 |
| Cai, N; Liu, NN; Zhao, N | 1 |
| Lv, QZ; Shen, FM; Xu, HB | 1 |
| Li, JY; Ma, JL; Pan, KF; Shen, L; You, WC; Zhang, L; Zhang, Y; Zhou, T | 1 |
| Boyken, J; Dahllöf, H; Laux-Biehlmann, A; Nagel, J; Schmidt, N; Zollner, TM | 1 |
| Aguado, A; Alonso, MJ; Avendaño, MS; Beltrán, LM; Briones, AM; Cachofeiro, MV; García-Puig, J; González-Amor, M; Guillem-Llobat, P; Martínez-Revelles, S; Palacios, R; Salaices, M; Simões, MR; Vassallo, DV; Vila, L | 1 |
| Endo, K; Kosaka, T; Sawaji, Y; Yamamoto, K; Yorifuji, M | 1 |
| Arantes, EC; Faccioli, LH; Hori, JI; Paula-Silva, FW; Serezani, CH; Sorgi, CA; Zamboni, DS; Zoccal, KF | 1 |
| Kamatham, AN; Kondreddy, VK | 1 |
| Esbona, K; Inman, D; Jeffery, J; Keely, P; Saha, S; Schedin, P; Wilke, L | 1 |
| Gao, JH; Huang, ZY; Liu, R; Tai, Y; Tang, CW; Tang, SH; Tang, YM; Tong, H; Wang, CH; Wen, SL; Yan, ZP; Yang, JH; Yang, WJ; Ye, C | 1 |
| Coletta, RD; Kabir, TD; Lambert, DW; Leigh, RJ; McCall, J; Mellone, M; Parkinson, EK; Paterson, IC; Prime, SS; Speight, PM; Tasena, H; Thomas, GJ; Zhou, D | 1 |
| Altavilla, D; Arcoraci, V; Bitto, A; Galfo, F; Irrera, N; Macrì, A; Minutoli, L; Pallio, G; Pizzino, G; Squadrito, F; Squadrito, G | 1 |
| Bajetto, A; Florio, T; Gatta, E; Novelli, F; Robello, M; Tasso, B; Thellung, S; Tonelli, M; Villa, V | 1 |
| Cheng, D; Han, C; Lv, H; Xie, Z; Ye, F; Yu, S; Zhang, H; Zhang, Z | 1 |
| Almendros, I; Campillo, N; Farré, R; Gozal, D; Montserrat, JM; Navajas, D; Nonaka, PN; Picado, C; Roca-Ferrer, J; Torres, M; Vilaseca, A | 1 |
| Chen, CH; Cheng, TS; Hsiao, PW; Hsu, TW; Huang, HP; Ko, CJ; Lai, PF; Lan, SW; Lee, MS; Lin, HH; Lin, HY; Lu, YC; Shyu, HY; Tsai, CH; Wu, SR | 1 |
| Baggstrom, MQ; Bertino, E; Cheney, RT; Edelman, MJ; Friedman, PN; Gajra, A; Hahn, OM; Hodgson, L; Milne, G; Mitchell-Richards, K; Molina, J; Reckamp, KL; Ritter, J; Schiller, JH; Stinchcombe, TE; Thomas, SP; Vokes, EE; Wang, X | 1 |
| Huang, G; Yang, S; Zhou, S | 1 |
| Cane, S; Hennequart, M; Hoffmann, D; Pilotte, L; Plaen, E; Stroobant, V; Van den Eynde, BJ | 1 |
| Ding, WY; Guan, PP; Guo, JW; Huang, XS; Wang, P; Wang, SL; Wang, ZY | 1 |
| Bastos-Pereira, AL; Dreifuss, AA; Fraga, D; Zampronio, AR | 1 |
| Caron, MM; Emans, PJ; Janssen, MP; Surtel, DA; van Rhijn, LW; van Rietbergen, B; Welting, TJ | 1 |
| Ahn, KI; Cha, HJ; Choi, EO; Choi, YH; Hong, SH; Hwang-Bo, H; Jeong, JW; Kim, GY; Kim, HJ; Kim, J; Kim, KY; Kim, MY; Kim, SG; Lee, HH; Lee, KW; Park, C | 1 |
| Chen, L; Li, D; Wu, X; Zhong, J | 1 |
| Goodman, SB; Jämsen, E; Lin, T; Lu, L; Nabeshima, A; Nathan, K; Pajarinen, J; Yao, Z | 1 |
| Dynybil, C; Perka, C; Plecko, M; Sauerschnig, M; Schlichting, K; Schmidt, C; Stolberg-Stolberg, J; Wienerroither, V | 1 |
| Hong, SW; Hur, DY; Jin, DH; Kim, B; Kim, D; Kim, J; Kim, S; Kim, YS | 1 |
| Hammock, BD; Harris, TR; Hwang, SH; Imai, DM; Kodani, S; Rand, AA; Yang, J | 1 |
| Alam, S; Ansari, KM; Ayanur, A; Bansal, M; Jagdale, P; Pal, S; Singh, N | 1 |
| Asaki, T; Fujita, M; Hasegawa, M; Higashino, K; Kawasaki, S; Koda, K; Morioka, Y; Sakurai, Y; Sanaki, T; Takahashi, T; Tofukuji, S; Yoneda, S; Yoshioka, T | 1 |
| Boulay, G; Broderick, KT; Burr, R; Comaills, V; Emmons, E; Haber, DA; Koulopoulos, MW; Kulkarni, AS; Maheswaran, S; Miyamoto, DT; Ramaswamy, S; Rengarajan, S; Rivera, MN; Shioda, T; Sil, S; Tai, E; Ting, DT; Toner, M; Wittner, BS; Wu, CL; Zheng, Y | 1 |
| Al-Khrasani, M; Balogh, M; Bató, E; Bihari, Z; Brenner, GB; Ferdinandy, P; Giricz, Z; Gyires, K; Helyes, Z; Hutka, B; Juhász, J; Kemény, Á; László, SB; László, T; Lázár, B; Makkos, A; Ostorházi, E; Szabó, D; Tiszlavicz, L; Zádori, ZS | 1 |
| Hendriks, J; Huang, X; Karperien, M; Lafeber, F; Mastbergen, S; Post, JN; van Helvoort, E; Zhong, L | 1 |
| Brauncajs, M; Jarzębska, M; Kowalski, ML; Kurowski, M; Lewandowska-Polak, A; Makowska, J; Pawełczyk, M | 1 |
| Ibi, K; Imai, K; Kihara, T; Nejishima, H; Ogawa, H; Senshu, M; Takeda, Y; Yonezawa, Y | 1 |
| Choi, HY; Jang, C; Lee, JY; Lee, KT; Park, CS; Youn, I; Yune, TY | 1 |
| Cai, JL; Cao, H; Chen, LK; Huang, YS; Li, RZ; Li, S; Lin, XM; Luo, W; Wang, H; Wang, TX; Wu, XP; Zhang, QH; Zhou, C | 1 |
| Filipowicz-Rachwał, A; Markowicz, J; Misiorek, M; Pichla, M; Uram, Ł; Wałajtys-Rode, E; Wołowiec, S | 1 |
| Deng, L; Feng, D; Liang, H; Liang, J; Ling, B; Yan, K; Zhang, X | 1 |
| Lai, R; Liang, Z; Liao, P; Wang, S; Xie, Z; Ye, Z; Zeng, L | 1 |
| Gorantla, VS; Herneisey, M; Janjic, BM; Janjic, JM; Karagoz, H; Komatsu, T; Liu, L; Loftus, S; Zor, F | 1 |
| Chen, J; Jing, H; Liu, X; Luo, L; Qin, T; Shen, Z; Wang, L; Wu, H; Xiong, L; Yang, N; Zhu, X | 1 |
| Mu, LL; Wei, YT; Wen, B; Wen, GR; Zhao, K | 1 |
| Abuo-Rahma, GEA; Allam, RM; El Subbagh, HI; El-Gamal, DA; Marzouk, AA; Mohamed, MFA; Moustafa, AH; Nafady, A | 1 |
| Jiang, M; Song, E; Song, Y; Zhang, P | 1 |
| Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K | 1 |
| Chi, J; Dai, Z; Hu, J; Huang, L; Ji, T; Li, J; Luo, Z; Wang, G; Wang, L; Wang, Z; Zhang, H; Zhou, C | 1 |
| Brox, R; Hackstein, H | 1 |
| Desind, SZ; Iacona, JR; Lutz, CS; Mitrofanova, A; Yu, CY | 1 |
| Abedipour, F; Ataee, M; Ghaznavi, H; Gorgani, F; Khorashad, ARS; Metanat, M; Mohammadghasemipour, Z; Mohammadi, M; Momeni, MK; Sargazi, S; Sartipi, M; Shahraki, O; Sheervalilou, R; Shirvaliloo, M | 1 |
| Cai, M; Ding, Y; Li, H; Li, S; Li, Y; Sun, Q; Xie, W; Zhang, Y | 1 |
| Abdel-Fattah, MM; Abo-El Fetoh, ME; Afify, H; Mohamed, WR; Ramadan, LAA | 1 |
| Ambs, S; Balamurugan, K; Czarra, K; Ewald, AJ; Krishnamurthy, S; McKennett, L; Padmanaban, V; Poria, DK; Sehareen, SW; Sharan, S; Sterneck, E; Tang, W; Ueno, NT | 1 |
| Cao, P; Chen, H; Hu, B; Li, J; Liang, L; Wang, J; Wang, Y; Wei, L; Wu, J; Wu, X; Xiao, Q; Xie, X; Xu, C; Yang, C; Yu, W; Zang, F; Zhang, R; Zhang, T; Zheng, G | 1 |
| Bai, D; He, X; Ito, K; Li, Y; Liu, K; Liu, Y; Ma, Y; Tan, H; Zhang, B; Zhang, Y; Zhen, W | 1 |
| Chen, Z; Lin, H; Pan, B; Qiu, J; Tang, N; Tu, H; Wang, Z; Wu, X; Yao, Y; Yu, L; Zhang, X | 1 |
| Carranza, C; Carreto-Binaghi, LE; Gonzalez, Y; Guzmán-Beltrán, S; Juárez, E; Muñoz-Torrico, M; Sartillo-Mendoza, LG; Torres, M | 1 |
8 review(s) available for celecoxib and dinoprostone
| Article | Year |
|---|---|
Outcome of specific COX-2 inhibition in rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Isoenzymes; Membrane Proteins; Peroxidases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Rats; Sulfonamides | 1997 |
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Depression, Chemical; Dinoprostone; Epoprostenol; Gastric Mucosa; Gastrointestinal Hemorrhage; Humans; Incidence; Intestinal Mucosa; Isoenzymes; Lactones; Membrane Proteins; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Randomized Controlled Trials as Topic; Substrate Specificity; Sulfonamides; Sulfones; Thromboembolism; Thromboxane A2; Treatment Outcome | 2001 |
[Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Prostaglandins G; Pyrazoles; Rheumatic Diseases; Sulfonamides; Sulfones | 2001 |
Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
Topics: Cardiotonic Agents; Cardiovascular Diseases; Cardiovascular System; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Dinoprostone; Disease Progression; Epoprostenol; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones | 2004 |
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Celecoxib; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Epidermal Growth Factor; Epoprostenol; Humans; Interleukin-12; Isoenzymes; Lactones; Matrix Metalloproteinases; Membrane Proteins; Neoplasms; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Signal Transduction; Sulfonamides; Sulfones; Thromboxane A2; Vascular Endothelial Growth Factor A | 2004 |
[Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials].
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Enzyme Inhibitors; Female; Humans; Isoenzymes; Membrane Proteins; Neoplasm Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Receptor, ErbB-2; Sulfonamides | 2004 |
[Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aromatase; Breast Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Female; Genes, erbB-2; Humans; Membrane Proteins; Mice; Neoplasm Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2004 |
Compositions for treatment of cancer and inflammation.
Topics: Apoptosis; Celecoxib; Cell Proliferation; Colorectal Neoplasms; Curcumin; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Synergism; Drug Therapy, Combination; Humans; Osteoarthritis; Pancreatic Neoplasms; Pyrazoles; Sulfonamides | 2008 |
31 trial(s) available for celecoxib and dinoprostone
| Article | Year |
|---|---|
Outcome of specific COX-2 inhibition in rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Isoenzymes; Membrane Proteins; Peroxidases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Rats; Sulfonamides | 1997 |
In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model.
Topics: Adult; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Humans; Ibuprofen; Isoenzymes; Male; Membrane Proteins; Microdialysis; Molar, Third; Oral Surgical Procedures; Pain Measurement; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Substrate Specificity; Sulfonamides; Thromboxane B2; Tooth Extraction | 2002 |
Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antigens, Neoplasm; Apoptosis; Blood Vessels; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Female; Humans; Immunoenzyme Techniques; Isoenzymes; Ki-67 Antigen; Lymphocytes; Membrane Proteins; Middle Aged; Neovascularization, Pathologic; Pilot Projects; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Serpins; Sulfonamides; Uterine Cervical Neoplasms | 2003 |
Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Biomarkers; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Dinoprostone; Double-Blind Method; Humans; Immunoenzyme Techniques; Intestinal Mucosa; Ki-67 Antigen; Mass Spectrometry; Middle Aged; Placebos; Pyrazoles; Remission Induction; Sulfonamides | 2004 |
Lack of effect of celecoxib on prostaglandin E2 concentrations in nipple aspirate fluid from women at increased risk of breast cancer.
Topics: Adult; Aged; Biomarkers; Breast Neoplasms; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Female; Humans; Middle Aged; Nipples; Pyrazoles; Risk Factors; Sulfonamides | 2004 |
Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.
Topics: Ascites; Celecoxib; Dinoprostone; Double-Blind Method; Female; Furosemide; Glomerular Filtration Rate; Humans; Kidney; Liver Cirrhosis; Male; Middle Aged; Naproxen; Platelet Aggregation; Pyrazoles; Renin; Sulfonamides | 2005 |
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Docetaxel; Endostatins; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Nausea; Neoplasm Recurrence, Local; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vomiting | 2005 |
Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aldosterone; Body Weight; Celecoxib; Creatinine; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Diuretics; Female; Furosemide; Humans; Indomethacin; Kidney; Potassium; Prostaglandins; Pyrazoles; Renin; Sodium; Sulfonamides; Thromboxane B2 | 2005 |
Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blotting, Western; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Depression, Chemical; Diclofenac; Dinoprostone; Female; Gene Expression; Humans; Interleukin-1; Knee Joint; Male; Membrane Proteins; Osteoarthritis, Knee; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Synovial Membrane; Time Factors; Tumor Necrosis Factor-alpha | 2006 |
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Depressive Disorder; Dinoprostone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inflammation; Interleukin-6; Lorazepam; Male; Middle Aged; Morpholines; Patient Dropouts; Pilot Projects; Psychological Tests; Pyrazoles; Reboxetine; Serotonin; Severity of Illness Index; Sulfonamides | 2006 |
Trial of celecoxib in amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Dinoprostone; Female; Humans; Male; Middle Aged; Patient Selection; Placebos; Pyrazoles; Sulfonamides; Treatment Outcome | 2006 |
Assessment of celecoxib pharmacodynamics in pancreatic cancer.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Female; Gene Expression; Humans; Immunohistochemistry; Male; Membrane Proteins; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; RNA, Messenger; Sulfonamides; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production.
Topics: Adult; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Female; Genotype; Heterozygote; Humans; Lipopolysaccharides; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrazoles; Sulfonamides | 2006 |
Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity.
Topics: Adult; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Drug Hypersensitivity; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Middle Aged; Pyrazoles; Single-Blind Method; Sulfonamides | 2008 |
Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women.
Topics: Adult; Aged; Aged, 80 and over; Body Fluids; Breast Neoplasms; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Female; Humans; Menopause; Middle Aged; Neoplasm Invasiveness; Nipples; Osmolar Concentration; Prognosis; Pyrazoles; Risk Factors; Specimen Handling; Suction; Sulfonamides | 2008 |
Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Thromboxane B2 | 2008 |
Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Chondrocytes; Cyclooxygenase 2; Diclofenac; Dinoprostone; Down-Regulation; Female; Humans; Interleukin-1; Male; Nitric Oxide; Osteoarthritis, Knee; Pyrazoles; Sulfonamides; Synovial Membrane | 2008 |
uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Celecoxib; Dinoprostone; Female; Humans; Middle Aged; Nipples; Plasminogen Activator Inhibitor 1; Postmenopause; Pyrazoles; Risk Factors; Sulfonamides; Up-Regulation; Urokinase-Type Plasminogen Activator | 2008 |
The chondroprotective effect of selective COX-2 inhibition in osteoarthritis: ex vivo evaluation of human cartilage tissue after in vivo treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Knee; Cartilage, Articular; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Indomethacin; Interleukin-1beta; Male; Matrix Metalloproteinases; Middle Aged; Nitric Oxide; Osteoarthritis, Knee; Proteoglycans; Pyrazoles; Sulfonamides; Synovial Membrane; Tumor Necrosis Factor-alpha | 2009 |
A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Dinoprostone; Feasibility Studies; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Mouth Neoplasms; Oncogene Protein v-akt; Pilot Projects; Precancerous Conditions; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Sulfonamides | 2008 |
A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise.
Topics: Adaptation, Physiological; Adult; Arm; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Double-Blind Method; Exercise; Female; Humans; Immunohistochemistry; Isometric Contraction; Leukocytes; Male; Microdialysis; Muscle Contraction; Muscle, Skeletal; Pain; Pyrazoles; Radionuclide Imaging; Recovery of Function; Satellite Cells, Skeletal Muscle; Sulfonamides; Young Adult | 2010 |
Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cells, Cultured; Chondrocytes; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Gene Expression; Humans; Immunohistochemistry; Osteoarthritis, Knee; Osteoprotegerin; Pyrazoles; RANK Ligand; Receptors, Prostaglandin E; Severity of Illness Index; Signal Transduction; Sulfonamides | 2010 |
Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining.
Topics: Adult; Aged; Carcinoma, Renal Cell; Celecoxib; Cyclooxygenase 2; Dendritic Cells; Dinoprostone; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Th1 Cells; Th1-Th2 Balance; Th2 Cells; Treatment Outcome | 2011 |
[Effect of cycloxygenase 2 inhibitor on levels of prostaglandin E2 in plasma and in local infiltrated fluid after functional endoscopic sinus surgery].
Topics: Adolescent; Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Endoscopy; Female; Humans; Male; Middle Aged; Nasal Septum; Nasal Surgical Procedures; Nose Diseases; Pain, Postoperative; Pyrazoles; Sinusitis; Sulfonamides; Young Adult | 2011 |
Vitamin D favorably alters the cancer promoting prostaglandin cascade.
Topics: Adult; Celecoxib; Cholecalciferol; Cyclooxygenase 2; Dinoprostone; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms; Placebos; Prostaglandin Antagonists; Pyrazoles; Reference Values; RNA; Sulfonamides; Transforming Growth Factor beta; Vitamin D | 2013 |
Cyclooxygenases 1 and 2 differentially regulate blood pressure and cerebrovascular responses to acute and chronic intermittent hypoxia: implications for sleep apnea.
Topics: Adult; Blood Pressure; Celecoxib; Cerebrovascular Circulation; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprost; Dinoprostone; Double-Blind Method; Epoprostenol; Female; Heart Rate; Humans; Hypoxia; Indomethacin; Male; Middle Aged; Pyrazoles; Sleep Apnea, Obstructive; Sulfonamides; Thromboxane A2 | 2014 |
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Dinoprostone; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models | 2015 |
Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib.
Topics: Adult; Celecoxib; Dinoprostone; Dose-Response Relationship, Drug; Epoprostenol; Female; Humans; Intramolecular Oxidoreductases; Male; Middle Aged; Prostaglandin-E Synthases; Young Adult | 2016 |
Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Celecoxib; China; Clarithromycin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Precancerous Conditions; Stomach; Stomach Neoplasms | 2015 |
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease-Free Survival; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Rate | 2017 |
Lipopolysaccharide-induced immune stress negatively regulates broiler chicken growth
Topics: Animals; Celecoxib; Chickens; Cyclooxygenase 2; Cytokines; Dinoprostone; Inflammation; Lipopolysaccharides; NF-kappa B; Signal Transduction | 2023 |
352 other study(ies) available for celecoxib and dinoprostone
| Article | Year |
|---|---|
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
Topics: Adenosine Triphosphate; Alprostadil; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Transport; Cell Line; Cell Membrane; Diffusion; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Humans; Insecta; Multidrug Resistance-Associated Proteins; Prostaglandins; Prostaglandins A; Prostaglandins F; Ribosomal Proteins; RNA Interference; RNA, Small Interfering; Thromboxane B2; Time Factors | 2003 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Chemical synthesis and biological evaluation of ω-hydroxy polyunsaturated fatty acids.
Topics: Analgesics; Animals; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Hydroxyeicosatetraenoic Acids; Pain; Pain Threshold; Rats; Transient Receptor Potential Channels | 2017 |
Pharmacological analysis of cyclooxygenase-1 in inflammation.
Topics: Animals; Arthritis, Experimental; Blood Platelets; Carrageenan; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Edema; Hyperalgesia; Indomethacin; Inflammation; Isoenzymes; Male; Membrane Proteins; Models, Biological; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Thromboxane B2 | 1998 |
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Epoprostenol; Female; Humans; Ibuprofen; Isoenzymes; Male; Membrane Proteins; Middle Aged; Monocytes; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thromboxane B2 | 1999 |
Kinetic basis for selective inhibition of cyclo-oxygenases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding, Competitive; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Ibuprofen; Indomethacin; Inhibitory Concentration 50; Isoenzymes; Kinetics; Male; Membrane Proteins; Mice; Naproxen; Oxygen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sheep; Structure-Activity Relationship; Sulfonamides; Tetramethylphenylenediamine; Thermodynamics | 1999 |
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Celecoxib; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Radiation; Feeding Behavior; Indomethacin; Isoenzymes; Mice; Mice, Hairless; Neoplasms, Radiation-Induced; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Skin Neoplasms; Sulfonamides; Ultraviolet Rays | 1999 |
Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Collagen; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Exudates and Transudates; Gastric Mucosa; Inflammation; Isoenzymes; Male; Membrane Proteins; Naproxen; Nitrates; Nitric Oxide Donors; Nitrites; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Thromboxanes; Wound Healing | 2000 |
Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Ductus Arteriosus; Epoprostenol; Female; Hemodynamics; In Vitro Techniques; Indomethacin; Isoenzymes; Nitrobenzenes; Nitroprusside; Oxygen; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pulmonary Artery; Pyrazoles; Sheep; Sulfonamides; Vasoconstriction; Vasodilator Agents | 2000 |
Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthritis; Atrial Fibrillation; Bicarbonates; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Gastric Mucosa; Gastrointestinal Hemorrhage; Hip Joint; Humans; Hypoprothrombinemias; Incidence; Intestinal Mucosa; Isoenzymes; Lactones; Male; Membrane Proteins; Mucus; Peroxidases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Warfarin | 2000 |
Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation.
Topics: Administration, Topical; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dermatitis; Dinoprostone; Edema; Epidermis; Female; Ibuprofen; Isoenzymes; Mice; Mice, Hairless; Neutrophils; Peroxidase; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Skin; Sulfonamides; Sunburn; Ultraviolet Rays | 2000 |
Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis.
Topics: Animals; Bone Resorption; Celecoxib; Cells, Cultured; Crosses, Genetic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Female; Interleukin-1; Interleukin-6; Isoenzymes; Macrophage Activation; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Osteoclasts; Osteolysis; Prostaglandin-Endoperoxide Synthases; Prostheses and Implants; Prosthesis Failure; Pyrazoles; Skull; Sulfonamides; Titanium; Tumor Necrosis Factor-alpha | 2001 |
Evaluation of the tocolytic effect of a selective cyclooxygenase-2 inhibitor in a mouse model of lipopolysaccharide-induced preterm delivery.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chorioamnionitis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprost; Dinoprostone; Ductus Arteriosus, Patent; Female; Interleukin-1; Interleukin-6; Isoenzymes; Lipopolysaccharides; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Models, Animal; Obstetric Labor, Premature; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Time Factors; Tocolysis; Tumor Necrosis Factor-alpha; Uterus | 2001 |
Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Inflammation; Interleukin-1; Isoenzymes; Male; NF-kappa B; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Transcription, Genetic; Tumor Necrosis Factor-alpha; Zymosan | 2001 |
Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Animals; Arachidonic Acid; Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase 2; Dinoprostone; Humans; Hydroxyeicosatetraenoic Acids; Isoenzymes; Leukemia; Lipoxygenase; Lung Neoplasms; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Tumor Cells, Cultured | 2001 |
Renocortical expression of renin and of cyclooxygenase-2 in response to angiotensin II AT1 receptor blockade is closely coordinated but not causally linked.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Gene Expression; Isoenzymes; Kidney Cortex; Male; Natriuresis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin; RNA, Messenger; Sulfonamides; Tetrazoles | 2001 |
Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E(2) release in the spinal cord.
Topics: Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Formaldehyde; Isoenzymes; Membrane Proteins; Microdialysis; Pain; Pain Measurement; Posterior Horn Cells; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Spinal Cord; Sulfonamides | 2001 |
A protective role for cyclooxygenase-2 in drug-induced liver injury in mice.
Topics: Acetaminophen; Animals; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; DNA Primers; Gene Expression Profiling; Immunoblotting; Isoenzymes; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Prostaglandin D2; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Survival Rate | 2001 |
Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Division; Colonic Neoplasms; Cornea; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; Isoenzymes; Membrane Proteins; Mice; Mice, Nude; Neovascularization, Pathologic; Neovascularization, Physiologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Sulfonamides; Thromboxane B2; Xenograft Model Antitumor Assays | 2002 |
Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Blood Platelets; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Humans; Indomethacin; Inhibitory Concentration 50; Isoenzymes; Lactones; Membrane Proteins; Models, Chemical; Models, Molecular; Monocytes; Prostaglandin-Endoperoxide Synthases; Protein Binding; Protein Conformation; Pyrazoles; Sulfonamides; Sulfones | 2002 |
Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Doxycycline; Enzyme-Linked Immunosorbent Assay; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Isoenzymes; Lactones; Male; Membrane Proteins; Models, Chemical; Oligonucleotides, Antisense; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Sulfones; Time Factors; Tumor Cells, Cultured | 2002 |
Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Alopecia; Animals; Carcinogens; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Female; Hair Follicle; Humans; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Inbred ICR; Mice, Transgenic; Phenotype; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Skin; Skin Neoplasms; Sulfonamides; Tetradecanoylphorbol Acetate | 2002 |
N-acetylcysteine and celecoxib lessen cadmium cytotoxicity which is associated with cyclooxygenase-2 up-regulation in mouse neuronal cells.
Topics: Acetylcysteine; Animals; Antioxidants; Base Sequence; Cadmium; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cysteine Endopeptidases; Dinoprostone; DNA Primers; Isoenzymes; Mice; Multienzyme Complexes; Neurons; Prostaglandin-Endoperoxide Synthases; Proteasome Endopeptidase Complex; Pyrazoles; Sulfonamides; Tumor Cells, Cultured; Ubiquitin; Up-Regulation | 2002 |
Chronic gastric ulcer healing in rats subjected to selective and non-selective cyclooxygenase-2 inhibitors.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dipyrone; Enzyme Inhibitors; Female; Gastric Mucosa; Isoenzymes; Male; Membrane Proteins; Omeprazole; Piroxicam; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors; Pyrazoles; Rats; Rats, Wistar; Stomach; Stomach Ulcer; Sulfonamides; Time Factors; Wound Healing | 2002 |
Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model.
Topics: Animals; Biopsy, Needle; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Mice; Mice, Hairless; Probability; Pyrazoles; Random Allocation; Skin Neoplasms; Statistics, Nonparametric; Sulfonamides; Treatment Outcome; Ultraviolet Rays | 2002 |
COX-2 and prostanoid receptors: good targets for chemoprevention.
Topics: Animals; Breast Neoplasms; Celecoxib; Cell Transformation, Neoplastic; Chemoprevention; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Enzyme Inhibitors; Female; Humans; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Knockout; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP1 Subtype; Sulfonamides | 2002 |
Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat.
Topics: Aging; Animals; Celecoxib; Cognition Disorders; Corticosterone; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Drug Administration Schedule; Encephalitis; Inflammation Mediators; Interleukin-1; Isoenzymes; Male; Maze Learning; Memory; Neurodegenerative Diseases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Tumor Necrosis Factor-alpha | 2002 |
Delta-opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Benzamides; Benzylidene Compounds; Celecoxib; Consciousness; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Heart Rate; Ischemic Preconditioning, Myocardial; Isoenzymes; Male; Myocardial Infarction; Myocardial Stunning; Myocardium; Naltrexone; Narcotic Antagonists; Nitrobenzenes; Piperazines; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rabbits; Receptors, Opioid, delta; Sulfonamides | 2002 |
Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colon; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diarrhea; Dinoprostone; Drug Administration Schedule; Drug Synergism; HT29 Cells; Humans; Irinotecan; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Weight Loss; Xenograft Model Antitumor Assays | 2002 |
Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
Topics: Animals; Arthritis, Experimental; Capillary Permeability; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Gastric Mucosa; Immunohistochemistry; Indomethacin; Isoenzymes; Lactones; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Stomach Ulcer; Sulfonamides; Sulfones | 2002 |
Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Head and Neck Neoplasms; Humans; Ileum; Intestinal Mucosa; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasm Transplantation; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Female; Humans; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Transgenic; Motor Neurons; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Survival Rate | 2002 |
Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Arthritis, Rheumatoid; Celecoxib; Cell Division; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Fibroblasts; Humans; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Synovial Membrane; Transcription Factors | 2002 |
PAR1-dependent and independent increases in COX-2 and PGE2 in human colonic myofibroblasts stimulated by thrombin.
Topics: Celecoxib; Cell Line; Colon; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Female; Fibroblast Growth Factor 2; Fibroblasts; Humans; Immunohistochemistry; Infant; Isoenzymes; Membrane Proteins; Muscle, Smooth; Peptide Fragments; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Receptor, PAR-1; Receptors, Thrombin; Sulfonamides; Thrombin | 2003 |
Proliferative activity of bile from congenital choledochal cyst patients.
Topics: Adolescent; Adult; Animals; Apoptosis; Bile; Carcinogens; Celecoxib; Cell Cycle; Cell Division; Child; Child, Preschool; Choledochal Cyst; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Female; Flow Cytometry; Humans; Isoenzymes; Male; Membrane Proteins; Middle Aged; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2003 |
Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dexamethasone; Dinoprostone; Edema; Indomethacin; Inflammation; Interleukin-1; Isoenzymes; Lactones; Male; Nitric Oxide; Peroxidase; Pleurisy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Sulfones; Thromboxane B2; Tumor Necrosis Factor-alpha | 2002 |
Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Celecoxib; Cell Division; Cholangiocarcinoma; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2003 |
Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bleomycin; Blotting, Western; Carcinoma; Celecoxib; Cell Line, Tumor; Cell Survival; Cisplatin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; DNA Fragmentation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Fluorouracil; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulindac; Time Factors; Vincristine | 2003 |
Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Isoenzymes; Liver Neoplasms; Membrane Proteins; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2003 |
Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer.
Topics: Administration, Topical; Animals; Celecoxib; Cell Division; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Epidermis; Female; Isoenzymes; Mice; Neoplasms, Radiation-Induced; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Skin Neoplasms; Sulfonamides; Ultraviolet Rays | 2003 |
Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Doxycycline; Drug Administration Schedule; Humans; Isoenzymes; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Membrane Proteins; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Osteosarcoma; Prostaglandin-Endoperoxide Synthases; Protease Inhibitors; Pyrazoles; Rhabdomyosarcoma, Embryonal; Soft Tissue Neoplasms; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Division; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Drug Synergism; Enalapril; Humans; Indomethacin; Isoenzymes; Male; Membrane Proteins; Mice; Prostaglandin-Endoperoxide Synthases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrazoles; Receptor, IGF Type 1; Sulfonamides | 2003 |
COX-2 inhibition and prostaglandin receptors in experimental nephritis.
Topics: Animals; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Female; Gene Expression Regulation; Glomerular Mesangium; Glomerulonephritis; Isoenzymes; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Receptors, Prostaglandin; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP3 Subtype; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides | 2003 |
Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers.
Topics: Aged; Bronchoalveolar Lavage; Bronchoscopy; Calcimycin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Feasibility Studies; Female; Humans; Interleukin-10; Ionophores; Lipopolysaccharides; Lung Neoplasms; Macrophages, Alveolar; Male; Middle Aged; Pilot Projects; Pyrazoles; Smoking; Sulfonamides; Tumor Cells, Cultured | 2003 |
Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat.
Topics: Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Ganglia, Spinal; Hyperalgesia; Ibuprofen; Isoenzymes; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Sciatic Neuropathy; Spinal Cord; Sulfonamides; Tumor Necrosis Factor-alpha | 2004 |
Chemoprevention of gastric cancer by celecoxib in rats.
Topics: Analysis of Variance; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Drug Administration Schedule; Indomethacin; Isoenzymes; Male; Methylnitronitrosoguanidine; Models, Animal; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sodium Chloride; Stomach Neoplasms; Sulfonamides | 2004 |
Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin.
Topics: Animals; Carcinogens; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Electrophoretic Mobility Shift Assay; Enzyme Activation; Enzyme Inhibitors; Female; Isoenzymes; Mice; Mice, Inbred ICR; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Pyrazoles; Skin; Sulfonamides; Tetradecanoylphorbol Acetate; Transcription Factor AP-1 | 2004 |
Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.
Topics: Animals; Antineoplastic Agents; Carcinoma; Celecoxib; Colonic Neoplasms; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Humans; Isoenzymes; Kinetics; Membrane Proteins; Mice; Mice, Inbred BALB C; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Time Factors | 2004 |
Cyclooxygenase-2-mediated prostaglandin E2 production in mesenteric lymph nodes and in cultured macrophages and dendritic cells after infection with Salmonella.
Topics: Administration, Oral; Animals; Bone Marrow Cells; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Dendritic Cells; Dinoprostone; Female; Isoenzymes; Lymph Nodes; Macrophages; Macrophages, Peritoneal; Mesentery; Mice; Mice, Inbred BALB C; Prostaglandin-Endoperoxide Synthases; Pyrazoles; RNA, Messenger; Salmonella Infections, Animal; Salmonella typhimurium; Sulfonamides | 2004 |
Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Carcinogens; Celecoxib; Cell Cycle; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Drug Synergism; Female; Fluorenes; Isoenzymes; Leucine; Mammary Neoplasms, Experimental; Methylnitrosourea; Prostaglandin D2; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Transcription Factors | 2004 |
Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Celecoxib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Tumor Suppressor Proteins | 2004 |
The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Caspase 9; Caspases; Celecoxib; Cell Death; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Chromones; Cyclooxygenase 2; Cytochromes c; Dinoprostone; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Immunoassay; Immunohistochemistry; Isoenzymes; Membrane Proteins; Microscopy, Fluorescence; Morpholines; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Sulfonamides; Threonine; Time Factors | 2004 |
Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Celecoxib; Cell Death; Cyclooxygenase 2; Dinoprostone; DNA; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Cells; Female; Immunohistochemistry; Isoenzymes; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mice; Mice, Hairless; Mitogen-Activated Protein Kinases; Models, Chemical; Neoplasms, Radiation-Induced; p38 Mitogen-Activated Protein Kinases; Papilloma; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Protein Binding; Pyrazoles; Sesquiterpenes; Skin Neoplasms; Sulfonamides; Time Factors; Transcription Factor AP-1; Transcription, Genetic; Transcriptional Activation; Ultraviolet Rays | 2004 |
Vascular and cellular responses to pro-inflammatory stimuli in rat dental pulp.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents; Calcitonin Gene-Related Peptide; Capillary Permeability; Celecoxib; Cyclooxygenase Inhibitors; Dental Pulp; Dexamethasone; Dinoprostone; Dose-Response Relationship, Drug; Leukocytes; Lipopolysaccharides; Male; Pulpitis; Pyrazoles; Rats; Skin; Substance P; Sulfonamides | 2004 |
Effects of bile from patient with transduodenal sphincteroplasty on the growth of human cholangiocarcinoma cell line.
Topics: Antineoplastic Agents; Bile; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Celecoxib; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; Cyclooxygenase 2; Dinoprostone; Humans; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; RNA, Messenger; Sphincterotomy, Transduodenal; Sulfonamides; Up-Regulation | 2004 |
Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Biomarkers, Tumor; Celecoxib; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dietary Supplements; Dinoprostone; Female; Immunohistochemistry; Isoenzymes; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Neovascularization, Pathologic; Proliferating Cell Nuclear Antigen; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Pyrazoles; RNA, Messenger; Sulfonamides | 2004 |
Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors.
Topics: Administration, Topical; Animals; Antimetabolites, Antineoplastic; Celecoxib; Cell Division; Cyclooxygenase Inhibitors; Dinoprostone; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Mice; Mice, Hairless; Pyrazoles; Skin; Skin Neoplasms; Sulfonamides; Ultraviolet Rays | 2004 |
Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats.
Topics: Animals; Celecoxib; Colon; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dextran Sulfate; Dinoprostone; Disease Models, Animal; Female; Indomethacin; Inflammatory Bowel Diseases; Male; Muscle Contraction; Oxidative Stress; Peroxidase; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2004 |
Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death.
Topics: Animals; Brain Edema; Celecoxib; Cerebral Hemorrhage; Collagenases; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Inflammation; Male; Neuroprotective Agents; Pyrazoles; Rats; Rats, Sprague-Dawley; Recovery of Function; Sulfonamides; Time Factors | 2004 |
Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dinoprostone; In Vitro Techniques; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Retina; Sulfonamides; Time Factors | 2004 |
Role of cyclooxygenase-2 in cytokine-induced beta-cell dysfunction and damage by isolated rat and human islets.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytokines; Dinoprostone; Dose-Response Relationship, Drug; Glucose; Humans; Insulin; Insulin Secretion; Interferon-gamma; Interleukin-1; Islets of Langerhans; Isoenzymes; Membrane Proteins; Nitric Oxide; Nitric Oxide Synthase; Nitrites; Prostaglandin-Endoperoxide Synthases; Protein Isoforms; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2004 |
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Body Weight; Celecoxib; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esophageal Neoplasms; Humans; Hydroxyurea; Immunohistochemistry; Leukotriene B4; Lipoxygenase Inhibitors; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2004 |
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Endothelial Cells; Fibroblast Growth Factor 2; Group IV Phospholipases A2; Humans; Indomethacin; Interleukin-8; Male; Membrane Proteins; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Phospholipases A; Phospholipases A2; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Endothelin-1; Fever; Indomethacin; Injections, Intraperitoneal; Injections, Intraventricular; Intubation, Gastrointestinal; Lipopolysaccharides; Male; Organic Chemicals; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2005 |
Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.
Topics: Amiloride; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Drug Therapy, Combination; Female; Isoenzymes; Lung Neoplasms; Mammary Neoplasms, Experimental; Neoplasm Invasiveness; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides; Urokinase-Type Plasminogen Activator | 2004 |
Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Celecoxib; Cell Division; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2004 |
Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells.
Topics: 6-Ketoprostaglandin F1 alpha; Amino Acid Substitution; Angiotensin-Converting Enzyme Inhibitors; Animals; Anthracenes; Aorta; Binding, Competitive; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; DNA; Endothelial Cells; Endothelium, Vascular; Enzyme Induction; Humans; JNK Mitogen-Activated Protein Kinases; Lung; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mutation, Missense; Oligodeoxyribonucleotides; Peptidyl-Dipeptidase A; Phosphorylation; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Prostaglandins I; Protein Processing, Post-Translational; Pyrazoles; Ramipril; Recombinant Fusion Proteins; Signal Transduction; Sulfonamides; Sus scrofa; Thromboxane A2; Transcription Factor AP-1; Transcription, Genetic; Transfection; Umbilical Veins | 2005 |
Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, Western; Celecoxib; Dietary Supplements; Dinoprostone; Disease Models, Animal; Immunohistochemistry; Male; Mice; Mice, Transgenic; Models, Biological; Phosphorylation; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Pyrazoles; Sulfonamides; Sulindac; Time Factors; Transgenes | 2004 |
Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid.
Topics: Animals; Celecoxib; Colitis; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Inflammation; Intestinal Mucosa; Male; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Trinitrobenzenesulfonic Acid | 2004 |
[Role of prostaglandin E2 in regulation of urine excretion in saluresis, water and osmotic diuresis in rat].
Topics: Animals; Celecoxib; Chlorides; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Diuresis; Diuretics; Furosemide; Male; Natriuresis; Osmosis; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Urination; Water | 2004 |
Selective COX-2 inhibitor regulates the MAP kinase signaling pathway in human osteoarthritic chondrocytes after induction of nitric oxide.
Topics: Annexin A5; Apoptosis; Blotting, Western; Cartilage; Celecoxib; Cell Separation; Chondrocytes; Culture Media, Conditioned; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Flow Cytometry; Glycosaminoglycans; Green Fluorescent Proteins; Humans; MAP Kinase Signaling System; Membrane Potentials; Membrane Proteins; Microscopy, Fluorescence; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitric Oxide; Osteoarthritis; p38 Mitogen-Activated Protein Kinases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Time Factors | 2005 |
Celecoxib inhibits ureteral contractility and prostanoid release.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Celecoxib; Cyclooxygenase Inhibitors; Depression, Chemical; Dimethyl Sulfoxide; Dinoprost; Dinoprostone; Gas Chromatography-Mass Spectrometry; Humans; Indomethacin; Muscle Contraction; Nitrobenzenes; Prostaglandin Antagonists; Prostaglandin D2; Prostaglandins; Pyrazoles; Secretory Rate; Sulfonamides; Sus scrofa; Thromboxane A2; Tumor Necrosis Factor-alpha; Ureter; Ureteral Obstruction | 2005 |
Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Bone Marrow; Carrier Proteins; Caspase 3; Caspase 9; Caspases; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Docetaxel; Drug Therapy, Combination; Enzyme Activation; Gene Expression Regulation, Enzymologic; Humans; Male; Membrane Proteins; Mice; Mice, Nude; Osteoblasts; Poly(ADP-ribose) Polymerases; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Stromal Cells; Sulfonamides; Taxoids; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2005 |
Adipose differentiation-related protein: a gonadotropin- and prostaglandin-regulated protein in primate periovulatory follicles.
Topics: Animals; Arachidonic Acid; Celecoxib; Cells, Cultured; Chorionic Gonadotropin; Cyclooxygenase Inhibitors; Dinoprostone; Female; Gene Expression Regulation; Gonadotropins; Granulosa Cells; Macaca mulatta; Membrane Proteins; Ovarian Follicle; Ovulation; Perilipin-2; Primates; Prostaglandins; Pyrazoles; RNA, Messenger; Sulfonamides | 2005 |
Individual and combined effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on endotoxin-induced periodontitis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Dinoprost; Dinoprostone; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Endotoxins; Fatty Acids, Omega-3; Leukotriene B4; Male; Periodontitis; Platelet Activating Factor; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides | 2005 |
Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Burkitt Lymphoma; Celecoxib; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Immunohistochemistry; In Vitro Techniques; Male; Mice; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Pyrazoles; Sulfonamides; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2005 |
Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Calcium Channel Blockers; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Humans; Indoles; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Signal Transduction; Sulfonamides; Transcriptional Activation; Triazoles | 2005 |
A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts.
Topics: Apoptosis; Blotting, Western; Caspase Inhibitors; Caspases; Celecoxib; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclooxygenase Inhibitors; Dinoprostone; DNA Fragmentation; Enzyme Inhibitors; Fibroblasts; Genes, bcl-2; Humans; Lactones; Pyrazoles; Sulfonamides; Sulfones; Synovial Membrane | 2005 |
Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway.
Topics: Amyloid beta-Peptides; Animals; Apoptosis; Butadienes; Celecoxib; Cyclooxygenase 2; Dinoprostone; Extracellular Signal-Regulated MAP Kinases; Imidazoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; NF-kappa B; Nitriles; p38 Mitogen-Activated Protein Kinases; PC12 Cells; Peptide Fragments; Poly(ADP-ribose) Polymerases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Rats; Sulfonamides; Up-Regulation | 2005 |
Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Female; Humans; In Vitro Techniques; Male; Nitric Oxide; Osteoarthritis; Proteoglycans; Pyrazoles; Sulfonamides | 2005 |
Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Taxoids | 2005 |
Celecoxib inhibits proliferation and induces apoptosis via cyclooxygenase-2 pathway in human pancreatic carcinoma cells.
Topics: Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2005 |
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.
Topics: Animals; Carcinoma, Pancreatic Ductal; Celecoxib; Cricetinae; Cyclooxygenase Inhibitors; Dinoprostone; Drug Therapy, Combination; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Liver; Liver Neoplasms; Pancreas; Pancreatic Neoplasms; Prostaglandins; Prostaglandins F; Pyrazoles; Sulfonamides | 2005 |
Effect of LLLT Ga-Al-As (685 nm) on LPS-induced inflammation of the airway and lung in the rat.
Topics: Animals; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Celecoxib; Chemotaxis, Leukocyte; Dinoprostone; Disease Models, Animal; Inflammation Mediators; Lipopolysaccharides; Low-Level Light Therapy; Male; Neutrophils; Pneumonia; Probability; Pyrazoles; Random Allocation; Rats; Reference Values; Sensitivity and Specificity; Sulfonamides; Trachea | 2005 |
Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication.
Topics: Celecoxib; Cell Line, Tumor; Chelating Agents; Cyclooxygenase 2; Dinoprostone; Glycoproteins; Hepacivirus; Humans; Membrane Proteins; NF-kappa B; Nitrobenzenes; Oxidative Stress; Phosphatidylinositol 3-Kinases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrrolidines; Reactive Oxygen Species; Replicon; RNA, Viral; Sulfonamides; Thiocarbamates | 2005 |
Neuroprotective effects of cyclooxygenase-2 inhibitor celecoxib against toxicity of LPS-stimulated macrophages toward motor neurons.
Topics: Animals; Celecoxib; Cell Line; Cell Survival; Cells, Cultured; Coculture Techniques; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Female; Interferon-gamma; Interleukin-1; Lipopolysaccharides; Macrophage Activation; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Motor Neurons; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase Type II; Pyrazoles; Radioimmunoassay; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Time Factors; Tumor Necrosis Factor-alpha | 2005 |
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Drug Interactions; Female; In Situ Nick-End Labeling; Lung Neoplasms; Mice; Mice, Nude; Pyrazoles; Sulfonamides; Transplantation, Heterologous | 2006 |
Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.
Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Fever; Fibroblasts; Humans; Hyperalgesia; In Vitro Techniques; Interleukin-1; Lipopolysaccharides; Lymphoma; Male; Membrane Proteins; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Sulfonamides; Thromboxane B2; Tumor Cells, Cultured | 2005 |
Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Celecoxib; Cells, Cultured; Chemokine CCL2; Chemokines; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Female; Humans; Macrophages; Male; Middle Aged; Neoplasm Proteins; Pyrazoles; Sulfonamides; Tissue Culture Techniques; Vascular Endothelial Growth Factor A | 2006 |
[A COX-2 inhibitor suppresses esophageal inflammation-metaplasia-adenocarcinoma sequence in rats].
Topics: Adenocarcinoma; Animals; Apoptosis; Barrett Esophagus; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Duodenogastric Reflux; Esophageal Neoplasms; Esophagus; Gastroesophageal Reflux; Male; Metaplasia; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides | 2005 |
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Cyclo-oxygenase-2 expression and prostaglandin E2 production in experimental chronic gastric ulcer healing.
Topics: Animals; Anti-Ulcer Agents; Blotting, Western; Celecoxib; Chronic Disease; Cyclooxygenase 2; Dinoprostone; Female; Gastric Mucosa; Male; Misoprostol; Omeprazole; Peroxidase; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Sulfonamides; Wound Healing | 2005 |
Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
Topics: Apoptosis; Blotting, Western; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Humans; Immunoenzyme Techniques; Laryngeal Neoplasms; Larynx; Membrane Proteins; Neoplasm Recurrence, Local; Papilloma; Papillomaviridae; Phosphatidylinositol 3-Kinases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Respiratory Tract Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sulfonamides | 2005 |
CC 05, a novel anti-inflammatory compound, exerts its effect by inhibition of cyclooxygenase-2 activity.
Topics: Animals; Anti-Inflammatory Agents; Baculoviridae; Benzenesulfonamides; Carrageenan; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Edema; Indomethacin; Inflammation; Inhibitory Concentration 50; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Spodoptera; Sulfonamides | 2005 |
Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways.
Topics: Apoptosis; Celecoxib; Cell Count; Cell Proliferation; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Gastrins; HT29 Cells; Humans; Isoenzymes; Membrane Proteins; Mitogen-Activated Protein Kinases; NF-kappa B; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2006 |
Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells.
Topics: Bronchi; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Epithelial Cells; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2005 |
The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer.
Topics: Aged; Aged, 80 and over; Blotting, Western; Caco-2 Cells; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colon; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Female; Gene Expression Regulation, Neoplastic; Histamine; Histidine Decarboxylase; HL-60 Cells; Humans; Intestinal Mucosa; Male; Middle Aged; Pyrazoles; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H2; Receptors, Histamine H4; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Time Factors; Up-Regulation; Vascular Endothelial Growth Factor A | 2005 |
Roles of cyclooxygenase 2 and microsomal prostaglandin E synthase 1 in rat acid reflux oesophagitis.
Topics: Animals; Celecoxib; Cell Division; Chronic Disease; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytosol; Dinoprostone; Epithelial Cells; Esophagitis, Peptic; Esophagus; Immunohistochemistry; Intramolecular Oxidoreductases; Male; Microsomes; Prostaglandin-E Synthases; Pyrazoles; Rats; Rats, Wistar; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides | 2006 |
Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors.
Topics: Animals; Apoptosis; Celecoxib; Cyclooxygenase Inhibitors; Dihematoporphyrin Ether; Dinoprostone; Drug Synergism; Inflammation; Interleukin-1; Interleukin-10; Mammary Neoplasms, Experimental; Mice; Neovascularization, Pathologic; Nitrobenzenes; Photochemotherapy; Photosensitizing Agents; Pyrazoles; Sulfonamides; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2005 |
Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.
Topics: Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; HCT116 Cells; Humans; Neoplasms; Pyrazoles; Radiation Tolerance; Radiation-Sensitizing Agents; Sulfonamides | 2005 |
Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Apoptosis; Celecoxib; Cell Adhesion; Cell Division; Curcumin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Drug Synergism; Humans; Lipid Peroxidation; Membrane Proteins; Osteoarthritis, Knee; Pyrazoles; Sulfonamides; Synovial Membrane | 2006 |
Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice.
Topics: Animals; Apoptosis; Celecoxib; Cyclooxygenase 2; Dinoprostone; Gastric Mucosa; Gastrins; Gene Expression; Hypertrophy; Mice; Mice, Transgenic; Pyrazoles; Stomach Neoplasms; Sulfonamides | 2006 |
Cyclooxygenase-2 inhibitory phenylbutenoids from the rhizomes of Zingiber cassumunar.
Topics: Animals; Celecoxib; Cell Line; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Macrophages; Molecular Conformation; Phenylbutyrates; Plant Roots; Pyrazoles; Rats; Structure-Activity Relationship; Sulfonamides; Zingiber officinale | 2005 |
Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Hindlimb; Osteoarthritis; Proteoglycans; Pyrazoles; Sulfonamides; Synovial Fluid; Synovitis | 2006 |
Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1.
Topics: 6-Ketoprostaglandin F1 alpha; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Female; Macrophages; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Naphthalenes; Pyrazoles; Sulfonamides | 2005 |
In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Membrane Proteins; Mice; Mice, Nude; Pyrazoles; Sulfonamides; Xenograft Model Antitumor Assays | 2005 |
Celecoxib could reverse the hypoxia-induced Angiopoietin-2 upregulation in gastric cancer.
Topics: Angiopoietin-2; Angiopoietins; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Sulfonamides; Up-Regulation | 2006 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |
Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner.
Topics: Animals; Celecoxib; Colorectal Neoplasms; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Down-Regulation; Enterocytes; Flow Cytometry; G2 Phase; Genes, ras; Humans; Pyrazoles; Rats; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Tumor Suppressor Protein p53 | 2006 |
Celecoxib inhibits nitric oxide production in chondrocytes of ligament-damaged osteoarthritic rat joints.
Topics: Animals; Anterior Cruciate Ligament; Celecoxib; Cells, Cultured; Chondrocytes; Cyclooxygenase Inhibitors; Dinoprostone; Indomethacin; Interleukin-1alpha; Knee Joint; Male; Nitric Oxide; Osteoarthritis; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2006 |
Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage.
Topics: Animals; Blood-Retinal Barrier; Capillary Permeability; Celecoxib; Cell Culture Techniques; Cyclooxygenase Inhibitors; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dinoprostone; Drug Carriers; Humans; Injections; Lactic Acid; Male; Microspheres; Pigment Epithelium of Eye; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Vascular Endothelial Growth Factor A | 2006 |
Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice.
Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apolipoproteins E; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Hypercholesterolemia; Male; Mice; Mice, Inbred C57BL; Prostaglandin D2; Pyrazoles; Sulfonamides | 2006 |
Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor.
Topics: Animals; Brain; Carrageenan; Celecoxib; Chlorobenzoates; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Edema; Fever; Hindlimb; Indoleacetic Acids; Lactones; Lipopolysaccharides; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones; Tissue Distribution | 2006 |
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.
Topics: Animals; Aromatase; Aromatase Inhibitors; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Mammary Glands, Animal; Mice; Mice, Transgenic; NIH 3T3 Cells; Pyrazoles; Receptor, ErbB-2; Sulfonamides | 2006 |
PGE2 produced by lung cancer suppresses immune function through T-regulatory cells and can be blocked by the COX2 inhibitor Celebrex.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Immune Tolerance; Lung Neoplasms; Pyrazoles; Sulfonamides; T-Lymphocytes, Regulatory | 2005 |
Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor.
Topics: Adenoma; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Administration Schedule; Intestinal Neoplasms; Lipoxygenase; Mice; Mice, Inbred C57BL; Pyrazoles; Receptors, Prostaglandin; Signal Transduction; Sulfonamides | 2006 |
Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor.
Topics: Actins; Animals; Cadherins; Celecoxib; Cell Line; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Dogs; Drug Interactions; Enzyme Activation; Epithelial Cells; Fibrosis; Hepatocyte Growth Factor; Kidney Failure, Chronic; Kidney Tubules; MAP Kinase Signaling System; Mesoderm; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pyrazoles; Sulfonamides; Transforming Growth Factor beta1 | 2006 |
Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.
Topics: Administration, Inhalation; Aerosols; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Celecoxib; Dinoprostone; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Injections, Intravenous; Interleukin-8; Lung Neoplasms; Mice; Neoplasm Transplantation; Pyrazoles; Sulfonamides; Taxoids; Transplantation, Heterologous | 2006 |
Interaction of macrophages with apoptotic cells enhances HIV Type 1 replication through PGE2, PAF, and vitronectin receptor.
Topics: Apoptosis; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Diterpenes; Ginkgolides; HIV-1; Humans; In Vitro Techniques; Integrin alphaVbeta3; Lactones; Macrophages; Phagocytosis; Platelet Activating Factor; Platelet Membrane Glycoproteins; Pyrazoles; Receptors, G-Protein-Coupled; Sulfonamides; Virus Replication | 2006 |
Acute pulmonary inflammation induced by exposure of the airways to staphylococcal enterotoxin type B in rats.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Benzoquinones; Bone Marrow; Bronchoalveolar Lavage Fluid; Celecoxib; Chemotaxis, Leukocyte; Cytokines; Dexamethasone; Dinoprostone; Dose-Response Relationship, Immunologic; Enterotoxins; Intubation, Intratracheal; Leukocyte Count; Leukotriene B4; Lipoxygenase Inhibitors; Male; Neutrophils; Pneumonia, Staphylococcal; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Time Factors | 2006 |
Increased Leishmania replication in HIV-1-infected macrophages is mediated by tat protein through cyclooxygenase-2 expression and prostaglandin E2 synthesis.
Topics: Animals; Antibodies, Viral; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Gene Products, tat; HIV Infections; HIV-1; Humans; Leishmania; Leishmaniasis; Macrophages; Pyrazoles; Sulfonamides; tat Gene Products, Human Immunodeficiency Virus; Transforming Growth Factor beta | 2006 |
Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Body Fluids; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Celecoxib; Cyclooxygenase 2 Inhibitors; Diarrhea; Dinoprostone; Dose-Response Relationship, Drug; Edema; Female; Humans; Middle Aged; Nipples; Patient Dropouts; Postmenopause; Premenopause; Pyrazoles; Risk Factors; Sulfonamides | 2006 |
[Prophylactic effect of a selective COX-2 inhibitor celecoxib on carcinogen-induced gastric premalignant lesions in rats].
Topics: Animals; Atrophy; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Gastric Mucosa; Male; Methylnitronitrosoguanidine; Precancerous Conditions; Pyrazoles; Random Allocation; Rats; Rats, Wistar; RNA, Messenger; Stomach; Stomach Neoplasms; Sulfonamides | 2006 |
Inhibition of prostaglandin F(2alpha) by selective cyclooxygenase 2 inhibitors accounts for reduced rat leukocyte migration.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Female; Indomethacin; Injections, Intraperitoneal; Lactones; Lipopolysaccharides; Neutrophil Infiltration; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones; Time Factors | 2005 |
Mucosal acid causes gastric mucosal microcirculatory disturbance in nonsteroidal anti-inflammatory drug-treated rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Dinoprostone; Endothelin-1; Gastric Acid; Gastric Mucosa; Male; Microcirculation; Pyrazoles; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Sulfonamides | 2007 |
Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells.
Topics: Aged; Animals; Antineoplastic Agents; Arachidonate 5-Lipoxygenase; bcl-2-Associated X Protein; Caco-2 Cells; Celecoxib; Cell Line; Cell Proliferation; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Female; HT29 Cells; Humans; Indoles; Lipoxygenase Inhibitors; Male; Membrane Proteins; Middle Aged; Pyrazoles; Receptors, Leukotriene; Sulfonamides | 2006 |
Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis.
Topics: Animals; Apoptosis; Celecoxib; Cell Proliferation; Chemokines; Chemotaxis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Dinoprostone; Female; Gene Expression; Growth Substances; Hepatitis, Animal; Hepatocytes; Immunoenzyme Techniques; Liver; Lymphocytes; Macrophages; Mice; Mice, Transgenic; NF-kappa B; Pyrazoles; Sulfonamides | 2007 |
Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Topics: Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dose-Response Relationship, Radiation; Humans; Male; Prostatic Neoplasms; Pyrazoles; Radiation Tolerance; Sulfonamides | 2007 |
Effect of different cyclooxygenase inhibitors on gastric adaptive cytoprotection induced by 20% ethanol.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytoprotection; Diclofenac; Dinoprostone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ethanol; Gastric Acid; Gastric Mucosa; Ibuprofen; Irritants; Male; Meloxicam; Membrane Proteins; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Pyrazoles; Rats; Rats, Wistar; Stomach Ulcer; Sulfonamides; Thiazines; Thiazoles | 2007 |
Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
Topics: Angiopoietin-1; Angiopoietin-2; Animals; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Glioblastoma; Humans; Male; Mice; Mice, Nude; Necrosis; Neoplasm Proteins; Neovascularization, Pathologic; Pyrazoles; Radiation Tolerance; Sulfonamides; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A | 2007 |
Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin.
Topics: Animals; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Drug Interactions; Gastric Mucosa; Hydrophobic and Hydrophilic Interactions; Male; Phosphatidylcholines; Pyrazoles; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Sulfonamides | 2007 |
Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Carcinoma; Celecoxib; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Dinoprostone; Down-Regulation; HT29 Cells; Humans; Pyrazoles; Sulfonamides | 2007 |
A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice.
Topics: Adenoma; Aging; Animals; Blotting, Western; Celecoxib; Cell Transformation, Neoplastic; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Epithelium; Female; Gene Dosage; Heterozygote; Homozygote; Humans; Inbreeding; Indomethacin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Ovarian Neoplasms; Ovary; Phenotype; Pyrazoles; Sulfonamides | 2007 |
The anti-cancer effect of COX-2 inhibitors on gastric cancer cells.
Topics: Adenocarcinoma; Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Microscopy, Fluorescence; Pyrazoles; Stomach Neoplasms; Sulfonamides; Tetrazolium Salts; Thiazoles | 2007 |
Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats.
Topics: Animals; Cardiovascular Diseases; Celecoxib; Colitis, Ulcerative; Colon; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dextran Sulfate; Dinoprostone; Disease Models, Animal; Gene Expression; Indomethacin; Male; Peroxidase; Plasma Substitutes; Pyrazoles; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrophotometry; Sulfonamides; Treatment Outcome | 2007 |
Synthesis and release of human cartilage matrix proteoglycans are differently regulated by nitric oxide and prostaglandin-E2.
Topics: Aged; Cartilage, Articular; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Interleukin-1; Male; Middle Aged; Nitric Oxide; Osteochondritis; Proteoglycans; Pyrazoles; Statistics, Nonparametric; Sulfonamides; Tissue Culture Techniques; Tumor Necrosis Factor-alpha | 2008 |
Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines.
Topics: 5-Lipoxygenase-Activating Proteins; Apoptosis; Blotting, Western; Carrier Proteins; Celecoxib; Cell Cycle; Cell Death; Cell Division; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Hydroxyeicosatetraenoic Acids; Indoles; Leukotriene B4; Lipoxygenase Inhibitors; Lung Neoplasms; Membrane Proteins; Pyrazoles; Quinolines; Spectrometry, Mass, Electrospray Ionization; Sulfonamides | 2007 |
Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition.
Topics: Animals; Apoptosis; Biomarkers; Cataract; Celecoxib; Cell Differentiation; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dog Diseases; Dogs; Epithelial Cells; In Vitro Techniques; Lactones; Lens, Crystalline; Mesoderm; Pyrazoles; Sulfonamides; Sulfones; Up-Regulation | 2007 |
Administration of cyclooxygenase-2 inhibitor reduces joint inflammation but exacerbates osteopenia in IL-1 alpha transgenic mice due to GM-CSF overproduction.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Bone Diseases, Metabolic; Bone Resorption; Celecoxib; Cells, Cultured; Coculture Techniques; Cyclooxygenase 2 Inhibitors; Dinoprostone; Granulocyte-Macrophage Colony-Stimulating Factor; Interleukin-1alpha; Mice; Mice, Inbred C3H; Mice, Transgenic; Osteoclasts; Osteogenesis; Pyrazoles; Sulfonamides | 2007 |
CCR1 and CCR5 chemokine receptors are involved in fever induced by LPS (E. coli) and RANTES in rats.
Topics: Analysis of Variance; Animals; Body Temperature; Celecoxib; Chemokine CCL5; Cyclooxygenase Inhibitors; Dinoprostone; Drug Interactions; Fever; Lipopolysaccharides; Male; Preoptic Area; Pyrazoles; Rats; Rats, Wistar; Receptors, CCR1; Receptors, CCR5; Receptors, Chemokine; Sulfonamides | 2007 |
Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.
Topics: Adenovirus E1A Proteins; Apoptosis; Blotting, Western; Breast Neoplasms; Celecoxib; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprost; Dinoprostone; Female; Flow Cytometry; Humans; Ovarian Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Sulfonamides; Transfection; Tumor Cells, Cultured | 2007 |
The pain game.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Drug Approval; Humans; Lactones; Mice; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2007 |
The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats.
Topics: Animals; Celecoxib; Consciousness; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Ischemic Preconditioning; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides; Time Factors; Up-Regulation | 2007 |
Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA.
Topics: Animals; Carrageenan; Celecoxib; Chlorobenzoates; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Hot Temperature; Hyperalgesia; Indoleacetic Acids; Inflammation; Male; Models, Biological; Pain; Pain Measurement; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Tissue Distribution | 2008 |
Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells.
Topics: Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Enzyme Activation; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Nitrobenzenes; Osteosarcoma; Pyrazoles; Sulfonamides | 2007 |
COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia.
Topics: Analgesia; Analgesics, Opioid; Analysis of Variance; Animals; Behavior, Animal; Blotting, Western; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Synergism; Female; Mammary Neoplasms, Animal; Mice; Mice, Inbred Strains; Morphine; Neoplasm Metastasis; Neovascularization, Pathologic; Pain; Pyrazoles; Sulfonamides; Tumor Burden | 2007 |
Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.
Topics: Active Transport, Cell Nucleus; Blotting, Western; Celecoxib; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cyclooxygenase 2; Dinoprostone; DNA Repair; DNA-Activated Protein Kinase; ErbB Receptors; Fibroblasts; HCT116 Cells; Humans; Pyrazoles; Radiation Tolerance; Radiation-Sensitizing Agents; Sulfonamides | 2008 |
Celecoxib inhibits production of MMP and NO via down-regulation of NF-kappaB and JNK in a PGE2 independent manner in human articular chondrocytes.
Topics: Aged; Cartilage, Articular; Celecoxib; Cells, Cultured; Chondrocytes; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Down-Regulation; Enzyme Activation; Humans; Interleukin-1beta; JNK Mitogen-Activated Protein Kinases; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Matrix Metalloproteinases; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphorylation; Pyrazoles; Sulfonamides | 2008 |
The effects of prostaglandin inhibition on whole-body ischemia-reperfusion in swine.
Topics: Animals; Cardiopulmonary Resuscitation; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Epoprostenol; Heart; Heart Arrest, Induced; Heart Massage; Indomethacin; Myocardium; Prostaglandins; Pyrazoles; Regional Blood Flow; Reperfusion Injury; Sulfonamides; Swine; Troponin I | 2008 |
Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Benzamides; Celecoxib; Cell Survival; Cells, Cultured; Collagen Type XI; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytochromes c; Dinoprostone; DNA Primers; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Immunoblotting; K562 Cells; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sulfonamides | 2008 |
Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
Topics: Analysis of Variance; Animals; BCG Vaccine; Blotting, Western; Carcinoma, Transitional Cell; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Humans; Immunotherapy; Mice; Pyrazoles; Sulfonamides; Treatment Outcome; Up-Regulation; Urinary Bladder Neoplasms | 2008 |
Editorial comment on: celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
Topics: Animals; BCG Vaccine; Carcinoma, Transitional Cell; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Immunotherapy; Mice; Pyrazoles; Sulfonamides; Treatment Outcome; Up-Regulation; Urinary Bladder Neoplasms | 2008 |
The effects of some nonsteroidal anti-inflammatory drugs on experimental induced gastric ulcers in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dipyrone; Ditiocarb; Gastric Acidity Determination; Gastric Mucosa; Histamine; Lipid Peroxides; Male; Malondialdehyde; Mucus; Peroxidase; Pyrazoles; Rats; Stomach Ulcer; Stress, Psychological; Sulfhydryl Compounds; Sulfonamides | 2007 |
Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Celecoxib; Cell Survival; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Dinoprostone; Immunohistochemistry; Killer Cells, Natural; Liver Neoplasms; Male; Neoplasm Metastasis; Neoplasm Transplantation; Neutrophil Infiltration; Prostaglandins; Pyrazoles; Rats; Sulfonamides; T-Lymphocytes | 2008 |
Cyclooxygenase-2/PGE2 pathway facilitates pentylenetetrazol-induced seizures.
Topics: Analysis of Variance; Animals; Antibodies; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Electroencephalography; Male; Pentylenetetrazole; Pyrazoles; Rats; Rats, Wistar; Seizures; Signal Transduction; Sulfonamides | 2008 |
Inhibition of mouse osteoblast proliferation and prostaglandin E2 synthesis by Ulmus davidiana Planch (Ulmaceae).
Topics: Actins; Animals; Celecoxib; Cell Cycle; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Immunoenzyme Techniques; Immunohistochemistry; Indomethacin; Mice; Mice, Inbred BALB C; Osteoblasts; Plant Bark; Plant Extracts; Proliferating Cell Nuclear Antigen; Prostaglandin Antagonists; Pyrazoles; Sulfonamides; Ulmus | 2008 |
TTX-R Na+ current-reduction by celecoxib correlates with changes in PGE(2) and CGRP within rat DRG neurons during acute incisional pain.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Calcitonin Gene-Related Peptide; Celecoxib; Cells, Cultured; Dinoprostone; Ganglia, Spinal; Male; Neurons, Afferent; Pain Measurement; Pain Threshold; Pain, Postoperative; Physical Stimulation; Pyrazoles; Rats; Rats, Sprague-Dawley; Sodium Channels; Sulfonamides; Time Factors; Treatment Outcome; Up-Regulation | 2008 |
Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Transitional Cell; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Flow Cytometry; Humans; Pilot Projects; Pyrazoles; Sulfonamides; Tumor Stem Cell Assay; Urinary Bladder Neoplasms | 2008 |
JP-8 jet fuel exposure rapidly induces high levels of IL-10 and PGE2 secretion and is correlated with loss of immune function.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Female; Hydrocarbons; Inhalation Exposure; Interleukin-10; Mice; Mice, Inbred C57BL; Models, Animal; Pyrazoles; Sulfonamides; Teratogens; Time Factors | 2007 |
Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Proliferation; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; HT29 Cells; Humans; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Caspase Inhibitors; Caspases; Celecoxib; Cell Cycle; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunoblotting; Immunoenzyme Techniques; Immunoprecipitation; Liver Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Trans-Activators; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Viral Regulatory and Accessory Proteins | 2009 |
Effects of chronic celecoxib on testicular function in normal and lipopolysaccharide-treated rats.
Topics: Animals; Base Sequence; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; DNA Primers; Lipopolysaccharides; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Testis | 2009 |
The anti-proliferative potency of celecoxib is not a class effect of coxibs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; beta Catenin; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Cyclin D; Cyclins; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Male; Mice; Mice, Nude; Poly(ADP-ribose) Polymerases; Proliferating Cell Nuclear Antigen; Pyrazoles; Sulfonamides; Tumor Burden | 2008 |
Celecoxib inhibits serum amyloid a-induced matrix metalloproteinase-10 expression in human endothelial cells.
Topics: Celecoxib; Cyclooxygenase 2; Dinoprostone; Endothelium, Vascular; Enzyme Induction; Gene Expression; Humans; Matrix Metalloproteinase 10; Matrix Metalloproteinase Inhibitors; Pyrazoles; Serum Amyloid A Protein; Sulfonamides | 2009 |
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dinoprostone; DNA, Complementary; DNA, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescence; Humans; Indoles; Mice; NF-kappa B; Pancreatic Neoplasms; Protein Binding; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Transfection; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2008 |
Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Caco-2 Cells; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Naproxen; Neoplasm Proteins; Pyrazoles; Reproducibility of Results; RNA, Messenger; Sulfonamides; Time Factors | 2008 |
Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Transformation, Neoplastic; Chronic Disease; Cyclooxygenase 2; Diet; Dinoprostone; Disease Models, Animal; Disease Progression; Genotype; Immunohistochemistry; Metaplasia; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Pancreatitis; Phenotype; Polymerase Chain Reaction; Pyrazoles; RNA; Sulfonamides | 2008 |
Cytokine-induced neutrophil chemoattractant (CINC)-1 induces fever by a prostaglandin-dependent mechanism in rats.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Celecoxib; Chemokine CXCL1; Dinoprostone; Dose-Response Relationship, Drug; Fever; Injections, Intraventricular; Male; Preoptic Area; Pyrazoles; Rats; Rats, Wistar; Statistics, Nonparametric; Sulfonamides | 2008 |
Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis.
Topics: Apoptosis; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Endometriosis; Endometrium; Epithelial Cells; Female; Humans; Immunohistochemistry; Infertility, Female; Pyrazoles; Sulfonamides | 2008 |
Synergistic anti-hyperalgesia of electroacupuncture and low dose of celecoxib in monoarthritic rats: involvement of the cyclooxygenase activity in the spinal cord.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Behavior, Animal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Electroacupuncture; Freund's Adjuvant; Hot Temperature; Humans; Hyperalgesia; Interleukin-1beta; Interleukin-6; Lumbar Vertebrae; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Spinal Cord; Sulfonamides; Tumor Necrosis Factor-alpha | 2008 |
Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Proliferation; Chemokines, C; Cricetinae; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Female; Ki-67 Antigen; Mesocricetus; Mucins; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; Nitrosamines; Pancreatic Neoplasms; Pyrazoles; Sesquiterpenes; Sulfonamides; Time Factors | 2008 |
Protective effects of butanol fraction from Betula platyphyla var. japonica on cartilage alterations in a rabbit collagenase-induced osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents; Betula; Cartilage, Articular; Celecoxib; Collagenases; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Gene Expression Regulation; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Osteoarthritis; Phytotherapy; Plant Bark; Plant Extracts; Plants, Medicinal; Proteoglycans; Pyrazoles; Rabbits; RNA, Messenger; Sulfonamides; Tissue Inhibitor of Metalloproteinase-1 | 2009 |
Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling.
Topics: Antineoplastic Agents; Blotting, Western; Caspase 9; Celecoxib; Cell Death; Cell Line, Tumor; Chromones; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Forkhead Transcription Factors; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indomethacin; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Signal Transduction; Stomach Neoplasms; Sulfonamides; Time Factors | 2009 |
Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Lipopolysaccharides; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; Pyrazoles; Sulfonamides; Toll-Like Receptor 2; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2009 |
Effects of nicotine and lipopolysaccharide on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in human osteoblasts.
Topics: Alkaline Phosphatase; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxygenase Inhibitors; Dinoprostone; Gene Expression Regulation; Humans; Lipopolysaccharides; Matrix Metalloproteinase 1; Matrix Metalloproteinases; Nicotine; Nicotinic Antagonists; Nitrobenzenes; Osteoblasts; Plasminogen Activators; Plasminogen Inactivators; Polymyxin B; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Tubocurarine | 2009 |
Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum.
Topics: Animals; Body Weight; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Dinoprostone; In Vitro Techniques; Liver; Liver Cirrhosis; Liver Diseases; Male; Necrosis; Organ Size; Pyrazoles; Random Allocation; Rats; Rats, Wistar; Serum; Sulfonamides; Swine | 2009 |
Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment.
Topics: Analysis of Variance; Animals; Celecoxib; Corticosterone; Corticotropin-Releasing Hormone; Cyclooxygenase Inhibitors; Depressive Disorder; Dinoprostone; Disease Models, Animal; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Exploratory Behavior; Gene Expression Regulation; Hippocampus; Interleukin-1; Male; Maze Learning; Nerve Growth Factor; Olfactory Bulb; Phospholipases A2; Platelet Aggregation Inhibitors; Pyrazoles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides | 2009 |
Prostaglandin involvement in hyperthermia induced by sleep deprivation: a pharmacological and autoradiographic study.
Topics: Animals; Autoradiography; Body Temperature; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Fever; Male; Prostaglandins; Pyrazoles; Rats; Rats, Wistar; Sleep Deprivation; Sulfonamides | 2009 |
Characterization and pharmacological evaluation of febrile response on zymosan-induced arthritis in rats.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Body Temperature; Celecoxib; Dexamethasone; Dinoprostone; Dipyrone; Dose-Response Relationship, Drug; Fever; Ibuprofen; Injections, Intra-Articular; Male; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Zymosan | 2009 |
Inflammatory mediators released following application of irritants on the rat injured incisors. The effect of treatment with anti-inflammatory drugs.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents; Capsaicin; Celecoxib; Dexamethasone; Dinoprostone; Endotoxins; Incisor; Indomethacin; Inflammation Mediators; Irritants; Morphine; Nerve Growth Factor; Pyrazoles; Rats; Rats, Sprague-Dawley; Sensory System Agents; Sulfonamides | 2009 |
Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice.
Topics: Animals; Blotting, Western; Carcinoma, Medullary; Caspase 3; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Sulfonamides; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2009 |
[Effects of celecoxib on PGE2 synthesis and COX-2 and VEGF-C mRNA expression in Tca8113 cell lines].
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Pyrazoles; RNA, Messenger; Sulfonamides; Tongue Neoplasms; Vascular Endothelial Growth Factor C | 2009 |
The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
Topics: Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Dendritic Cells; Dinoprostone; Forkhead Transcription Factors; Immune Tolerance; Indoleamine-Pyrrole 2,3,-Dioxygenase; Lung Neoplasms; Mice; Mice, Inbred C57BL; Pyrazoles; Sulfonamides; T-Lymphocytes, Regulatory | 2009 |
Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling.
Topics: Animals; beta Catenin; Bone Morphogenetic Proteins; Carrier Proteins; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Hamartoma; Intramolecular Oxidoreductases; Keratin-19; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Prostaglandin-E Synthases; Pyrazoles; RNA, Messenger; Signal Transduction; Stomach Diseases; Sulfonamides; Wnt1 Protein | 2009 |
A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2.
Topics: Animals; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Dinoprostone; Gene Expression Regulation; Growth Differentiation Factor 15; Humans; Intestinal Polyps; Mice; Mice, Inbred C57BL; Pyrazoles; Sulfonamides | 2009 |
Influence of COX-2-induced PGE2 on the initiation and progression of tail regeneration in Northern House Gecko, Hemidactylus flaviviridis.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Etoricoxib; Female; Lizards; Male; Pyrazoles; Pyridines; Regeneration; Sulfonamides; Sulfones; Tail | 2008 |
The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Edema; Extremities; Fever; Freund's Adjuvant; Hyperalgesia; Hypothalamus; Inflammation; Male; Pain Measurement; Phenylpropionates; Piroxicam; Pyrazoles; Rats; Rats, Inbred Lew; Rats, Wistar; Sulfonamides | 2009 |
IL-1beta stimulates the expression of prostaglandin receptor EP4 in human chondrocytes by increasing production of prostaglandin E2.
Topics: Celecoxib; Cells, Cultured; Chondrocytes; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Interleukin-1beta; Pyrazoles; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides | 2009 |
Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.
Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dinoprostone; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Interleukin-6; Male; Middle Aged; Prospective Studies; Pyrazoles; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sulfonamides; Surveys and Questionnaires; Young Adult | 2009 |
Cyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activation.
Topics: Ataxia Telangiectasia Mutated Proteins; Butadienes; Celecoxib; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Dinoprostone; DNA Damage; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Humans; Nitriles; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazoles; Signal Transduction; Sulfonamides; Tumor Suppressor Protein p53; Up-Regulation | 2009 |
Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs.
Topics: Animals; Blotting, Western; Caspase 3; Celecoxib; Cyclooxygenase Inhibitors; Cyclosporine; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Female; Immunohistochemistry; Immunosuppressive Agents; Mice; Neoplasms, Radiation-Induced; Pyrazoles; Sirolimus; Skin Neoplasms; Sulfonamides; Tumor Suppressor Protein p53; Ultraviolet Rays | 2010 |
Therapeutic effect of Aralia cordata extracts on cartilage protection in collagenase-induced inflammatory arthritis rabbit model.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Aralia; Arthritis; Cartilage; Caspase 3; Celecoxib; Chondrocytes; Collagenases; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Down-Regulation; Inflammation Mediators; Phytotherapy; Plant Extracts; Pyrazoles; Rabbits; Sulfonamides | 2009 |
[Celecoxib promotes apoptosis of breast cancer cell line MDA-MB-231 through down-regulation of the NF-kappaB pathway].
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Pyrazoles; RNA, Messenger; Signal Transduction; Sulfonamides; Transcription Factor RelA | 2009 |
Inhibition of prostaglandin E(2) signaling through the EP(1) receptor does not affect prostacyclin production in human endothelial cells.
Topics: Blood Coagulation; Bridged Bicyclo Compounds; Caproates; Cardiovascular Diseases; Celecoxib; Cell Line; Cytokines; Dinoprostone; Endothelial Cells; Epoprostenol; Fibrinolytic Agents; Gene Expression Regulation; Humans; Peroxisome Proliferator-Activated Receptors; Pyrazoles; Receptors, Prostaglandin E; Response Elements; Signal Transduction; Sulfonamides; Thromboplastin | 2009 |
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Lung Neoplasms; Lymphangiogenesis; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; Mice, Nude; Phenotype; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor C; Vesicular Transport Proteins | 2009 |
Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats.
Topics: Adenocarcinoma; Animals; Apoptosis; Azoxymethane; Blotting, Western; Carcinogens; Celecoxib; Cell Proliferation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Drug Therapy, Combination; Immunoenzyme Techniques; In Situ Nick-End Labeling; Male; Maximum Tolerated Dose; Membrane Proteins; Pyrazoles; Pyrimidines; Rats; Rats, Inbred F344; Sulfonamides; Tumor Suppressor Protein p53 | 2009 |
[Chemoprevention of Barrett's esophagus by celecoxib in rats].
Topics: Animals; Barrett Esophagus; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides | 2009 |
The effects of nepafenac and amfenac on retinal angiogenesis.
Topics: Analysis of Variance; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Epithelial Cells; Gene Expression Regulation; Humans; Neuroglia; Oxygen; Phenylacetates; Prostaglandins; Pyrazoles; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Retina; Retinal Neovascularization; Retinal Vessels; Sulfonamides; Vascular Endothelial Growth Factor A | 2010 |
COX-2 inhibitors are contraindicated for treatment of combined injury.
Topics: Animals; Body Weight; Celecoxib; Contraindications; Cyclooxygenase Inhibitors; Cytokines; Dinoprostone; Female; Mice; Pyrazoles; Radiation Injuries; Sulfonamides | 2009 |
Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines.
Topics: Adult; Age of Onset; Blotting, Western; Cadherins; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Mutational Analysis; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Middle Aged; Mutation; Netherlands; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Sulfonamides; Tissue Array Analysis | 2009 |
Compressive force induces osteoclast differentiation via prostaglandin E(2) production in MC3T3-E1 cells.
Topics: 3T3 Cells; Acid Phosphatase; Alkaline Phosphatase; Animals; Celecoxib; Cell Differentiation; Culture Media, Conditioned; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Gene Expression; Isoenzymes; Macrophage Colony-Stimulating Factor; Macrophages; Mice; Osteoclasts; Osteoprotegerin; Pyrazoles; RANK Ligand; Skull; Stress, Mechanical; Sulfonamides; Tartrate-Resistant Acid Phosphatase | 2010 |
Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Celecoxib; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Female; Genes, erbB-2; Immunohistochemistry; Mice; Mice, Transgenic; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2010 |
Vascular endothelial growth factor and not cyclooxygenase 2 promotes endothelial cell viability in the pancreatic tumor microenvironment.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Endothelium, Vascular; Humans; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Tumor Cells, Cultured; Vascular Endothelial Growth Factors | 2010 |
IL-1beta suppresses the formation of osteoclasts by increasing OPG production via an autocrine mechanism involving celecoxib-related prostaglandins in chondrocytes.
Topics: Animals; Autocrine Communication; Base Sequence; Celecoxib; Cell Differentiation; Cell Line; Cells, Cultured; Chondrocytes; Culture Media, Conditioned; Dinoprostone; DNA Primers; Gene Expression; Humans; Inflammation Mediators; Interleukin-1beta; Macrophage Colony-Stimulating Factor; Mice; Osteoclasts; Osteoprotegerin; Prostaglandins; Pyrazoles; RANK Ligand; Sulfonamides | 2009 |
Cyclooxygenase-derived mediators regulate the immunological control of Strongyloides venezuelensis infection.
Topics: Animals; Ascitic Fluid; Blood; Bronchoalveolar Lavage Fluid; Celecoxib; Dinoprostone; Duodenum; Enzyme Inhibitors; Eosinophils; Ibuprofen; Indomethacin; Leukocytes, Mononuclear; Lung; Male; Mice; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Strongyloides; Strongyloidiasis; Sulfonamides; Th1 Cells; Th2 Cells | 2010 |
Role of COX-2 in nonsteroidal anti-inflammatory drug enteropathy in rodents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Dinoprostone; Flurbiprofen; Inflammation; Intestine, Small; Male; Mice; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides | 2010 |
Anti-inflammatory effects of celecoxib in rat lungs with smoke-induced emphysema.
Topics: Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Celecoxib; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; I-kappa B Proteins; Inflammation; Macrophages; Male; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphorylation; Pulmonary Alveoli; Pulmonary Emphysema; Pyrazoles; Rats; Rats, Sprague-Dawley; Smoking; Sulfonamides | 2010 |
Celecoxib increases retinoid sensitivity in human colon cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Dinoprostone; HT29 Cells; Humans; Nitrobenzenes; Pyrazoles; Receptors, Retinoic Acid; Sulfonamides; Tretinoin | 2010 |
Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzofurans; Carcinoma, Squamous Cell; Celecoxib; Cell Division; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Synergism; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Pyrazoles; Salvia miltiorrhiza; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |
Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Enzyme Inhibitors; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyrazoles; Sulfonamides; Up-Regulation; Xenograft Model Antitumor Assays | 2010 |
Celecoxib combined with atorvastatin prevents progression of atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Celecoxib; Chemokine CCL2; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Progression; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Pyrazoles; Pyrroles; Sulfonamides; Vascular Cell Adhesion Molecule-1 | 2010 |
Targeting the tumor microenvironment using photodynamic therapy combined with inhibitors of cyclooxygenase-2 or vascular endothelial growth factor.
Topics: Animals; Celecoxib; Cell Line, Tumor; Cell Transformation, Neoplastic; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dihematoporphyrin Ether; Dinoprostone; Female; Humans; Injections; Light; Mice; Neoplasms; Nitrobenzenes; Photochemotherapy; Pyrazoles; Skin; Sulfonamides; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
IL-17A stimulates the expression of inflammatory cytokines via celecoxib-blocked prostaglandin in MC3T3-E1 cells.
Topics: 3T3 Cells; Animals; Bone Remodeling; Celecoxib; Cycloheximide; Cyclooxygenase 2 Inhibitors; Cytokines; Dental Stress Analysis; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Inflammation Mediators; Interleukin-17; Interleukins; Mice; Osteoblasts; Polymerase Chain Reaction; Prostaglandin-Endoperoxide Synthases; Protein Synthesis Inhibitors; Pyrazoles; RNA, Messenger; Sulfonamides | 2010 |
The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathway.
Topics: Animals; Arachidonic Acid; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Liver Neoplasms; Metabolic Networks and Pathways; Mice; Phospholipases A2; Pyrazoles; Sulfonamides | 2010 |
Indomethacin promotes adipogenesis of mesenchymal stem cells through a cyclooxygenase independent mechanism.
Topics: Adipogenesis; Animals; beta Catenin; CCAAT-Enhancer-Binding Protein-beta; Celecoxib; Cell Line; Cyclooxygenase 2; Dinoprostone; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Indomethacin; Ligands; Mesenchymal Stem Cells; Mice; PPAR gamma; Pyrazoles; Response Elements; Sulfonamides; Transcriptional Activation | 2010 |
Cox-2 inhibition attenuates cardiovascular and inflammatory aspects in monosodium glutamate-induced obese rats.
Topics: Adipose Tissue; Animals; Blood; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Heart; Heart Rate; Hypertension; Inflammation; Lipid Peroxidation; Lipid Peroxides; Liver; Male; Myocardium; Nitrates; Obesity; Pyrazoles; Rats; Rats, Wistar; Sodium Glutamate; Sulfonamides | 2010 |
Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats.
Topics: Analgesics; Analysis of Variance; Animals; Celecoxib; Dinoprostone; Hyperalgesia; Indomethacin; Inflammation; Morphine; Pain Threshold; Physical Stimulation; Pyrazoles; Rats; Sulfonamides | 2010 |
Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Adhesion; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Down-Regulation; Extracellular Matrix; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Pyrazoles; Sulfonamides; Tongue Neoplasms | 2010 |
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.
Topics: Animals; Blotting, Western; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dendritic Cells; Dinoprostone; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Immune Tolerance; Immunoenzyme Techniques; Immunotherapy; Mesothelioma; Mice; Mice, Inbred BALB C; Myeloid Cells; Nitric Oxide; Pyrazoles; Reactive Oxygen Species; Sulfonamides; T-Lymphocytes | 2010 |
COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer.
Topics: Adenocarcinoma; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Humans; Lung Neoplasms; Lymphangiogenesis; Lymphatic Metastasis; Mice; Mice, Nude; Pyrazoles; RNA, Small Interfering; Sulfonamides; Transplantation, Heterologous; Vascular Endothelial Growth Factor C | 2010 |
Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis.
Topics: Acute Kidney Injury; Animals; Arachidonic Acid; Blood Urea Nitrogen; Celecoxib; Cisplatin; Creatinine; Cyclooxygenase 2 Inhibitors; Dinoprostone; Gene Expression; Interleukin-1beta; Intramolecular Oxidoreductases; Male; Mice; Mice, Knockout; Prostaglandin-E Synthases; Pyrazoles; Reactive Oxygen Species; RNA, Messenger; Signal Transduction; Sulfonamides; Tumor Necrosis Factor-alpha | 2011 |
Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts.
Topics: 3T3 Cells; Acid Phosphatase; Animals; Bone Resorption; Carbonic Anhydrase II; Cathepsin K; Celecoxib; Cell Differentiation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Gene Expression Regulation, Enzymologic; Gene Silencing; Interleukin-17; Isoenzymes; Matrix Metalloproteinase 9; Mice; Osteoblasts; Osteoclasts; Pyrazoles; RANK Ligand; RNA, Messenger; RNA, Small Interfering; Sulfonamides; Tartrate-Resistant Acid Phosphatase | 2011 |
Prostaglandin E₂ signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors.
Topics: Animals; Antibodies, Neutralizing; Benzamides; Celecoxib; Cell Line; Cell Transformation, Neoplastic; Chemokine CCL2; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Dinoprostone; Female; Gastric Mucosa; Germ-Free Life; Helicobacter felis; Helicobacter Infections; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Stomach Neoplasms; Sulfonamides; Tumor Necrosis Factor-alpha; Wnt Proteins; Wnt1 Protein | 2011 |
Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Barrett Esophagus; CDX2 Transcription Factor; Celecoxib; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Esophagus; Gene Expression Profiling; Helicobacter Infections; Helicobacter pylori; Histocytochemistry; Homeodomain Proteins; Immunohistochemistry; Male; Microscopy; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Transcription Factors | 2011 |
Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity.
Topics: Acetaminophen; Adaptive Immunity; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Immunity, Innate; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Liver; Lung; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Pyrazoles; Respiratory Tract Infections; Sulfonamides; Viral Load; Virus Shedding | 2011 |
Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation.
Topics: Animals; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Fibroblast Growth Factor 2; Fibroblasts; Glycoproteins; Granulation Tissue; Injections, Subcutaneous; Intramolecular Oxidoreductases; Lymphangiogenesis; Lymphatic Vessels; Macrophages; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Prostaglandin-E Synthases; Pyrazoles; Receptors, Prostaglandin E, EP1 Subtype; Receptors, Prostaglandin E, EP2 Subtype; Receptors, Prostaglandin E, EP3 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Signal Transduction; Sulfonamides; Time Factors; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor D; Vascular Endothelial Growth Factor Receptor-3 | 2011 |
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
Topics: Alleles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; CD8-Positive T-Lymphocytes; Celecoxib; Chemokine CCL2; Chemokine CXCL10; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Glioma; Lysosomal-Associated Membrane Protein 1; Male; Mice; Mice, Inbred C57BL; Myeloid Cells; Pyrazoles; Sulfonamides; T-Lymphocytes, Cytotoxic | 2011 |
Effect of celecoxib on the antihypertensive effect of losartan in a rat model of renovascular hypertension.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Interactions; Hypertension, Renovascular; Losartan; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Renin; Sulfonamides | 2011 |
[Celecoxib increased cellular ATRA sensitivity of human colon cancer cell lines through COX-2-independent mechanisms].
Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Synergism; HT29 Cells; Humans; Nitrobenzenes; Pyrazoles; Receptors, Retinoic Acid; Sulfonamides; Tretinoin | 2009 |
Role of nitric oxide-synthase and cyclooxygenase/lipooxygenase systems in development of experimental ulcerative colitis.
Topics: Acetic Acid; Animals; Antioxidants; Arachidonate 5-Lipoxygenase; Arginine; Benzoquinones; Celecoxib; Colitis, Ulcerative; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Female; Guanidines; Indomethacin; Intestine, Large; Leukotriene B4; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidative Stress; Pyrazoles; Rats; Sulfonamides | 2011 |
Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytokines; Dinoprostone; Esophagitis, Peptic; Esophagus; Gastric Acid; Humans; Indomethacin; Male; Nitric Oxide; Nitric Oxide Donors; Nitroglycerin; Pyrazoles; Rats; Rats, Wistar; RNA, Messenger; Sulfonamides | 2011 |
Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A₂ and peroxisome proliferator-activated receptor gamma.
Topics: Animals; Apoptosis; Arachidonic Acids; Area Under Curve; Carcinoma, Lewis Lung; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Phospholipases A2, Cytosolic; PPAR gamma; Pyrazoles; Sulfonamides | 2011 |
The cyclooxygenase-2 pathway via the PGE₂ EP2 receptor contributes to oligodendrocytes apoptosis in cuprizone-induced demyelination.
Topics: Animals; Apoptosis; Caspase 3; Cattle; Celecoxib; Chelating Agents; Cuprizone; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Demyelinating Diseases; Dinoprostone; Fluorescent Antibody Technique; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myelin Sheath; Oligodendroglia; Postural Balance; Pyrazoles; Real-Time Polymerase Chain Reaction; Receptors, Prostaglandin E, EP2 Subtype; Signal Transduction; Sulfonamides; Xanthones | 2012 |
Soybean isoflavone genistein regulates apoptosis through NF-κB dependent and independent pathways.
Topics: Animals; Apoptosis; Blotting, Western; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Electrophoretic Mobility Shift Assay; Enzyme-Linked Immunosorbent Assay; Genistein; Glycine max; In Situ Nick-End Labeling; NF-kappa B; Pyrazoles; Reactive Oxygen Species; Sulfonamides | 2013 |
Cox-2 inhibitors induce early c-Myc downregulation and lead to expression of differentiation markers in leukemia cells.
Topics: Antigens, Differentiation; Apoptosis; Biomarkers; Celecoxib; Cell Differentiation; Cell Proliferation; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Down-Regulation; Gene Expression Regulation, Leukemic; Humans; Interphase; Jurkat Cells; K562 Cells; Nitrobenzenes; p38 Mitogen-Activated Protein Kinases; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-myc; Pyrazoles; Sulfonamides; U937 Cells; Up-Regulation | 2011 |
Protection against titanium particle-induced osteoclastogenesis by cyclooxygenase-2 selective inhibitor.
Topics: Acid Phosphatase; Animals; Bone Resorption; Cathepsin K; Celecoxib; Cell Differentiation; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Isoenzymes; Macrophages; Mice; Osteoclasts; Prosthesis Failure; Pyrazoles; Receptor Activator of Nuclear Factor-kappa B; Sulfonamides; Tartrate-Resistant Acid Phosphatase; Titanium | 2011 |
Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target.
Topics: Adult; Animals; Antiviral Agents; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Child; Child, Preschool; Cyclooxygenase 2 Inhibitors; Cytomegalovirus; Dinoprostone; Female; Ganciclovir; Humans; Infant; Male; Medulloblastoma; Mice; Mice, Nude; Middle Aged; Pyrazoles; Sulfonamides; Valganciclovir; Virus Replication; Xenograft Model Antitumor Assays; Young Adult | 2011 |
Dimethylcelecoxib induces an inhibitory complex consisting of HDAC1/NF-κB(p65)RelA leading to transcriptional downregulation of mPGES-1 and EGR1.
Topics: Celecoxib; Dinoprostone; Early Growth Response Protein 1; Electrophoretic Mobility Shift Assay; Female; HeLa Cells; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoprecipitation; Intramolecular Oxidoreductases; Methylation; Promoter Regions, Genetic; Prostaglandin-E Synthases; Protein Binding; Pyrazoles; RNA, Small Interfering; Signal Transduction; Sulfonamides; Transcription Factor RelA; Transcription, Genetic; Transcriptional Activation; Uterine Cervical Neoplasms | 2012 |
Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells.
Topics: Animals; Aspirin; Celecoxib; Cell Line; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Down-Regulation; Etoricoxib; I-kappa B Proteins; Inflammation Mediators; Intramolecular Oxidoreductases; Lipopolysaccharides; Membrane Proteins; Mice; Microglia; NF-kappa B; NF-KappaB Inhibitor alpha; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphorylation; Prostaglandin-E Synthases; Pyrazoles; Pyridines; RNA, Messenger; Sulfonamides; Sulfones | 2012 |
Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition.
Topics: Catechin; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Screening Assays, Antitumor; Epithelial-Mesenchymal Transition; Humans; Melanoma; Neoplasm Invasiveness; NF-kappa B; Pyrazoles; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP2 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Tea; Tetradecanoylphorbol Acetate; Transcription Factor RelA | 2011 |
PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.
Topics: Biphenyl Compounds; CD11b Antigen; Celecoxib; Cell Movement; Cells, Cultured; Chemokine CXCL12; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Monocytes; Myeloid Cells; Ovarian Neoplasms; Prostaglandin Antagonists; Pyrazoles; Receptors, CXCR4; Receptors, Prostaglandin E, EP2 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Tumor Cells, Cultured; Tumor Microenvironment; Xanthones | 2011 |
Prostaglandin E(2) potentiates methylmalonate-induced seizures.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Electrodes, Implanted; Electroencephalography; Male; Methylmalonic Acid; Parietal Lobe; Pyrazoles; Rats; Rats, Wistar; Seizures; Sulfonamides | 2012 |
Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.
Topics: Angiogenesis Inhibitors; Celecoxib; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Drug Synergism; Epithelial Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Hydroxyprostaglandin Dehydrogenases; Indomethacin; Lung Neoplasms; Pyrazoles; Sulfonamides; Vorinostat | 2013 |
Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
Topics: Aspirin; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Survival; Chemokine CXCL10; Chemokine CXCL9; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Female; Humans; Indomethacin; Interferon-gamma; Pyrazoles; Sulfonamides; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2012 |
Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
Topics: AC133 Antigen; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Biomarkers, Tumor; Carcinoma; Celecoxib; Colorectal Neoplasms; Combined Modality Therapy; Dinoprostone; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Indomethacin; Male; Middle Aged; Peptides; Pyrazoles; Randomized Controlled Trials as Topic; Real-Time Polymerase Chain Reaction; Statistics, Nonparametric; Sulfonamides; Transcription, Genetic | 2012 |
Expression of selected genes in preterm premature rupture of fetal membranes.
Topics: Adult; Calcium Channel Blockers; Calcium Channels, L-Type; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Endometritis; Female; Fetal Membranes, Premature Rupture; Gene Expression Profiling; Gene Expression Regulation, Developmental; Humans; Nifedipine; Obstetric Labor, Premature; Oxytocics; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Premature Birth; Pyrazoles; RNA, Messenger; Sulfonamides; Term Birth; Tocolytic Agents; Vasotocin | 2012 |
Ellagic acid facilitates indomethacin-induced gastric ulcer healing via COX-2 up-regulation.
Topics: Animals; Blotting, Western; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytokines; Dinoprostone; Dose-Response Relationship, Drug; Ellagic Acid; Enzyme-Linked Immunosorbent Assay; Gastric Mucosa; Indomethacin; Intercellular Signaling Peptides and Proteins; Male; Mice; Molecular Structure; Nitrobenzenes; Peroxidase; Pyrazoles; Stomach Ulcer; Sulfonamides; Time Factors; Up-Regulation; Wound Healing | 2012 |
Production and actions of the anandamide metabolite prostamide E2 in the renal medulla.
Topics: Angiotensin II; Animals; Arachidonic Acids; Arterial Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Endocannabinoids; Glycerides; Kidney Cortex; Kidney Medulla; Kinetics; Lipids; Male; Mice; Mice, Inbred C57BL; Microsomes; Polyunsaturated Alkamides; Potassium; Pyrazoles; Renal Circulation; Sodium; Sulfonamides | 2012 |
Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E(2) production.
Topics: Animals; Celecoxib; Cell Adhesion; Cell Line; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Farnesol; Humans; Interleukin-2; Jurkat Cells; Mice; Mice, Inbred BALB C; Oncogene Protein p21(ras); Phosphorylation; Pyrazoles; Salicylates; Sulfonamides; T-Lymphocytes | 2012 |
Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma.
Topics: Basement Membrane; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Lactones; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Pyrazoles; Sarcoma, Ewing; Sulfonamides; Sulfones | 2012 |
Activation of mitochondrial apoptosis pathways in cutaneous squamous cell carcinoma cells by diclofenac/hyaluronic acid is related to upregulation of Bad as well as downregulation of Mcl-1 and Bcl-w.
Topics: Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytochromes c; Diclofenac; Dinoprostone; Down-Regulation; Humans; Hyaluronic Acid; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Skin Neoplasms; Sulfonamides; Up-Regulation | 2012 |
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Gene Expression; HT29 Cells; Humans; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Celecoxib and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed mice.
Topics: Animals; Arachidonate 5-Lipoxygenase; Celecoxib; Cell Movement; Cell Proliferation; Cyclic AMP; Cyclooxygenase 2; Dinoprostone; Epinephrine; gamma-Aminobutyric Acid; Humans; Immunoassay; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Pyrazoles; Stress, Physiological; Sulfonamides; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Involvement of PGE2 and RANTES in Staphylococcus aureus-induced fever in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Ascitic Fluid; Celecoxib; Chemokine CCL5; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dipyrone; Fever; Hypothalamus; Male; Pyrazoles; Rats; Rats, Wistar; Signal Transduction; Staphylococcal Infections; Staphylococcus aureus; Sulfonamides | 2012 |
Cyclooxygenase (COX)-1 and COX-2 both play an important role in the protection of the duodenal mucosa in cats.
Topics: Animals; Blotting, Western; Cats; Celecoxib; Cimetidine; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diet; Dinoprostone; Duodenal Diseases; Duodenum; Female; Histamine H2 Antagonists; Immunohistochemistry; Intestinal Mucosa; Male; Pyrazoles; Sulfonamides | 2013 |
Cyclooxygenase-2 inhibition for the prevention of subglottic stenosis.
Topics: Animals; Celecoxib; Cicatrix; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Interleukin-1beta; Laryngostenosis; Mucous Membrane; Pyrazoles; Rabbits; Sulfonamides; Wound Healing | 2012 |
Effect of sphingosine kinase 1 inhibition on blood pressure.
Topics: Animals; Base Sequence; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Epoprostenol; Gene Knockdown Techniques; Human Umbilical Vein Endothelial Cells; Humans; Hypertension; Intramolecular Oxidoreductases; Male; MAP Kinase Signaling System; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mitochondrial Proteins; Phosphotransferases (Alcohol Group Acceptor); Prostaglandin-E Synthases; Pyrazoles; RNA, Small Interfering; Sulfonamides | 2013 |
Celecoxib antagonizes the cytotoxic effect of cisplatin in human gastric cancer cells by decreasing intracellular cisplatin accumulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Transport; Cation Transport Proteins; Celecoxib; Cell Line, Tumor; Cell Survival; Cisplatin; Copper Transporter 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Adducts; Drug Interactions; Female; Gene Expression; Humans; Inhibitory Concentration 50; Intracellular Fluid; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrazoles; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Angiostatic properties of sulindac and celecoxib in the experimentally induced inflammatory colorectal cancer.
Topics: 1,2-Dimethylhydrazine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Dinoprostone; Interferon-gamma; Interleukin-1beta; Interleukin-2; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; NF-kappa B; Nitric Oxide Synthase Type II; Pyrazoles; Rats; Rats, Sprague-Dawley; RNA, Messenger; STAT3 Transcription Factor; Sulfonamides; Sulindac | 2013 |
The anti-inflammatory effect of cyclooxygenase inhibitors in fibroblast-like synoviocytes from the human temporomandibular joint results from the suppression of PGE2 production.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Culture Techniques; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Female; Fibroblasts; Humans; Indomethacin; Interleukin-1beta; Interleukin-6; Male; Pyrazoles; Receptors, Prostaglandin E, EP2 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Synovial Membrane; Synovitis; Temporomandibular Joint Disorders; Young Adult | 2013 |
Expression of LGR-5, MSI-1 and DCAMKL-1, putative stem cell markers, in the early phases of 1,2-dimethylhydrazine-induced rat colon carcinogenesis: correlation with nuclear β-catenin.
Topics: 1,2-Dimethylhydrazine; Adenoma; Animals; beta Catenin; Biomarkers, Tumor; Celecoxib; Cell Nucleus; Cell Transformation, Neoplastic; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Doublecortin Protein; Doublecortin-Like Kinases; Fluorescent Antibody Technique; Immunohistochemistry; Intestinal Mucosa; Male; Neoplastic Stem Cells; Nerve Tissue Proteins; Precancerous Conditions; Protein Serine-Threonine Kinases; Pyrazoles; Rats; Rats, Inbred F344; Receptors, G-Protein-Coupled; RNA-Binding Proteins; Sulfonamides; Time Factors | 2013 |
Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.
Topics: Animals; Apoptosis; Celecoxib; Cell Line, Tumor; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Female; Genetic Therapy; Humans; Hydroxyprostaglandin Dehydrogenases; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Myeloid Cells; Neovascularization, Pathologic; Pyrazoles; Spleen; Sulfonamides; Tumor Burden | 2013 |
Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer.
Topics: Carcinoma, Squamous Cell; Celecoxib; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Extracellular Signal-Regulated MAP Kinases; Humans; Mouth Neoplasms; Nicotine; Phosphorylation; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2012 |
Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Dinoprostone; Drug Synergism; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; Sorafenib; Sulfonamides; Tumor Cells, Cultured | 2013 |
Yin-Yang regulation of prostaglandins and nitric oxide by PGD2 in human arthritis: reversal by celecoxib.
Topics: Celecoxib; Cells, Cultured; Chondrocytes; Dinoprost; Dinoprostone; Humans; Inflammation Mediators; Interleukin-1beta; Knee; Leukotriene B4; Nitric Oxide; Osteoarthritis; Prostaglandin D2; Prostaglandins F; Pyrazoles; Sulfonamides; Thromboxane B2 | 2013 |
Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23.
Topics: Arthritis, Rheumatoid; CD4 Antigens; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Fibroblasts; Humans; Inflammation; Interferon-gamma; Interleukin-17; Interleukin-1beta; Interleukin-23 Subunit p19; Interleukin-6; Interleukin-8; Leukocyte Common Antigens; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Middle Aged; Pyrazoles; Receptors, CCR6; Sulfonamides; Synovial Membrane; Th17 Cells; Tumor Necrosis Factor-alpha | 2013 |
Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Caspases; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Dinoprostone; Endothelium, Vascular; Female; Food Preservatives; Humans; Isothiocyanates; Muscle, Skeletal; Neoplasm Invasiveness; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2013 |
Sphingosine 1-phosphate (S1P) induces COX-2 expression and PGE2 formation via S1P receptor 2 in renal mesangial cells.
Topics: Angiotensin II; Animals; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Gene Expression Regulation, Enzymologic; Humans; Interleukin-1beta; Lysophospholipids; Male; MAP Kinase Signaling System; Mesangial Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Sulfonamides; Up-Regulation; Vasoconstrictor Agents | 2014 |
Low doses of celecoxib attenuate gut barrier failure during experimental peritonitis.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Ileum; Intestinal Mucosa; Mice; Mice, Inbred C57BL; Peritonitis; Permeability; Pyrazoles; Sulfonamides | 2013 |
COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: role of NFATc3.
Topics: Animals; Animals, Newborn; Calcineurin; Cardiomegaly; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclosporine; Dinoprostone; Endothelin-1; Gene Expression Regulation; Myocytes, Cardiac; Natriuretic Peptide, Brain; NFATC Transcription Factors; Nitrobenzenes; Primary Cell Culture; Promoter Regions, Genetic; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sulfonamides; Transcription, Genetic | 2014 |
Enhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cancer Vaccines; Celecoxib; Cell Line, Tumor; Chemotherapy, Adjuvant; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dendritic Cells; Dinoprostone; Disease Models, Animal; Female; Glioma; Immunotherapy; Interleukin-12; Lymphocytes, Tumor-Infiltrating; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; T-Lymphocytes, Cytotoxic; Time Factors; Tumor Necrosis Factor-alpha | 2013 |
Effects of rebamipide on nephrotoxicity associated with selected NSAIDs in rats.
Topics: Alanine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cell Adhesion Molecules; Creatinine; Diclofenac; Dinoprostone; Drug Interactions; Kidney; Kidney Diseases; Male; Nitric Oxide; Potassium; Pyrazoles; Quinolones; Rats; Rats, Sprague-Dawley; Sodium; Sulfonamides | 2013 |
Celecoxib potentially inhibits metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated β-catenin pathway.
Topics: Animals; Antigens, CD; beta Catenin; Cadherins; Celecoxib; Cell Line, Tumor; Cell Proliferation; Dinoprostone; Down-Regulation; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Phosphorylation; Pyrazoles; RNA, Messenger; RNA, Small Interfering; Sulfonamides; Up-Regulation | 2014 |
Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE₂.
Topics: Adoptive Transfer; Ampicillin; Animals; Anti-Bacterial Agents; Aspirin; Candida; Candidiasis; Cefoperazone; Celecoxib; Clindamycin; Cyclooxygenase Inhibitors; Dinoprostone; Dysbiosis; Feces; Gastrointestinal Tract; Inflammation; Lung; Macrophage Activation; Macrophages, Alveolar; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrazoles; Sulfonamides | 2014 |
PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Growth Processes; Cell Line, Tumor; Cyclooxygenase 2; Dinoprostone; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genes, myc; Genes, Tumor Suppressor; Humans; Lung Neoplasms; MicroRNAs; Proto-Oncogene Proteins c-myc; PTEN Phosphohydrolase; Pyrazoles; RNA, Long Noncoding; Sulfonamides; Up-Regulation | 2014 |
A three-dimensionally engineered biomimetic cartilaginous tissue model for osteoarthritic drug evaluation.
Topics: Animals; Apoptosis; Biomimetics; Cartilage, Articular; Celecoxib; Cell Differentiation; Cell Line; Cell Proliferation; Chondrocytes; Collagen Type II; Dinoprostone; Down-Regulation; Drug Evaluation; Extracellular Matrix; Gene Expression; Glycosaminoglycans; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Mice; Nitric Oxide; Osteoarthritis; Tissue Engineering; Transplants; Up-Regulation | 2014 |
COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis.
Topics: Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Celecoxib; Cell Cycle; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Synergism; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, B-Cell; Mesenchymal Stem Cells; Myeloid Cell Leukemia Sequence 1 Protein; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2014 |
COX-2 overexpression increases malignant potential of human glioma cells through Id1.
Topics: Animals; Celecoxib; Cell Line, Tumor; Cell Transformation, Neoplastic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioma; Humans; Inhibitor of Differentiation Protein 1; Mice; Mitotic Index; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrazoles; Spheroids, Cellular; Sulfonamides; Tumor Burden; Tumor Stem Cell Assay; Up-Regulation | 2014 |
Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Progression; Flow Cytometry; Fluorescent Antibody Technique; Humans; Hyaluronan Receptors; Immunoenzyme Techniques; Liver Neoplasms; Male; Neoplastic Stem Cells; PPAR gamma; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazoles; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sulfonamides; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation | 2014 |
Sinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expression.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Celecoxib; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Cyclooxygenase 2; Dinoprostone; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Morphinans; NF-kappa B; Pyrazoles; Signal Transduction; Sulfonamides | 2014 |
Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer.
Topics: Animals; Breast Neoplasms; Celecoxib; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Female; Humans; Lymphangiogenesis; Lymphatic Metastasis; Lymphatic Vessels; Mice; Mice, Inbred BALB C; Pregnancy; Puerperal Disorders; Pyrazoles; Sulfonamides; Tumor Microenvironment | 2014 |
Statins enhance rotator cuff healing by stimulating the COX2/PGE2/EP4 pathway: an in vivo and in vitro study.
Topics: Animals; Atorvastatin; Biomechanical Phenomena; Celecoxib; Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Animal; Pyrazoles; Pyrroles; Random Allocation; Rats, Wistar; Receptors, Prostaglandin E, EP4 Subtype; Rotator Cuff; Sulfonamides; Tendons; Wound Healing | 2014 |
The mechanism of COX-2 regulating HERG channel in gastric cancer cells.
Topics: Celecoxib; Cell Culture Techniques; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Pyrazoles; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Sulfonamides | 2014 |
Prostanoid induces premetastatic niche in regional lymph nodes.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Celecoxib; Cell Line, Tumor; Chemokine CXCL12; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dendritic Cells; Dinoprostone; Drug Screening Assays, Antitumor; Gene Knockout Techniques; Lung Neoplasms; Lymph Nodes; Lymphangiogenesis; Lymphatic Metastasis; Male; Mice, Knockout; Neoplasm Transplantation; Pyrazoles; Receptors, CXCR4; Receptors, Prostaglandin E, EP3 Subtype; Signal Transduction; Sulfonamides; T-Lymphocytes, Regulatory | 2014 |
Paeonol exerts an anticancer effect on human colorectal cancer cells through inhibition of PGE₂ synthesis and COX-2 expression.
Topics: Acetophenones; Animals; Apoptosis; Caspase 3; Celecoxib; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclooxygenase 2; Dinoprostone; Gene Expression Regulation, Neoplastic; Humans; Membrane Potential, Mitochondrial; Mice; NF-kappa B; Pyrazoles; Sulfonamides | 2014 |
Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cetuximab; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Head and Neck Neoplasms; Humans; In Vitro Techniques; Mice; Mice, Nude; Mouth Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Squamous Cell Carcinoma of Head and Neck; Sulfonamides; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Vascular endothelial growth factor plays a critical role in the formation of the pre-metastatic niche via prostaglandin E2.
Topics: Animals; Breast Neoplasms; Celecoxib; Cell Movement; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Lung; Lung Neoplasms; Mice, Inbred BALB C; Neoplasm Transplantation; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2014 |
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.
Topics: Animals; Antibodies, Neutralizing; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Resistance, Neoplasm; Female; Humans; Male; Mice; Neoplastic Stem Cells; Pyrazoles; Signal Transduction; Sulfonamides; Urinary Bladder Neoplasms; Wound Healing; Xenograft Model Antitumor Assays | 2015 |
Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Azoxymethane; Carcinogens; Celecoxib; Chemoprevention; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Hydroxyprostaglandin Dehydrogenases; Inflammation; Intestinal Mucosa; Membrane Proteins; Mice; Mice, Knockout; Pyrazoles; Sulfonamides; Sulindac | 2015 |
Silencing of COX-2 by RNAi modulates epithelial-mesenchymal transition in breast cancer cells partially dependent on the PGE2 cascade.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cadherins; Celecoxib; Cell Adhesion; Cell Movement; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Epithelial-Mesenchymal Transition; Female; Flow Cytometry; Fluorescent Antibody Technique; Gene Silencing; Humans; Immunoenzyme Techniques; Proto-Oncogene Proteins c-akt; Pyrazoles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sulfonamides; Tumor Cells, Cultured | 2014 |
Central mediators involved in the febrile response induced by polyinosinic-polycytidylic acid: lack of involvement of endothelins and substance P.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies; Body Temperature; Celecoxib; Central Nervous System; Cytokines; Dinoprostone; Endothelin B Receptor Antagonists; Fever; Indomethacin; Interferon Inducers; Male; Oligopeptides; Peptides; Piperidines; Poly I-C; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Tropanes | 2015 |
Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway.
Topics: Animals; Blood Vessels; Breast Neoplasms; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cytokines; Dinoprostone; Disease Models, Animal; Endothelial Cells; Female; Inflammation; Lipopolysaccharides; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Receptors, Prostaglandin E; Vascular Endothelial Growth Factor A; Xanthones | 2015 |
Determining cyclooxygenase-2 activity in three different test systems utilizing online-solid phase extraction-liquid chromatography-mass spectrometry for parallel quantification of prostaglandin E(2), D(2) and thromboxane B(2).
Topics: Celecoxib; Cell Line; Chromatography, Liquid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dexamethasone; Dinoprostone; Humans; Indomethacin; Lipopolysaccharides; Monocytes; Prostaglandin D2; Pyrazoles; Recombinant Proteins; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Tandem Mass Spectrometry; Thromboxane B2 | 2015 |
Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection.
Topics: Animals; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Celecoxib; Cell Survival; Dinoprostone; Female; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Transgenic; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins; Pyrazoles; Receptors, Prostaglandin E, EP2 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Signal Transduction; Sulfonamides; T-Lymphocytes, Cytotoxic | 2015 |
Induction of COX-2-PGE2 synthesis by activation of the MAPK/ERK pathway contributes to neuronal death triggered by TDP-43-depleted microglia.
Topics: Amyotrophic Lateral Sclerosis; Animals; Astrocytes; Celecoxib; Cell Death; Cell Line; Cyclooxygenase 2; Dinoprostone; DNA-Binding Proteins; Gene Expression Regulation; Humans; MAP Kinase Signaling System; Mice; Microglia; Mitogen-Activated Protein Kinase Kinases; Motor Neurons; Nerve Degeneration | 2015 |
Cyclic mechanical stretching induces autophagic cell death in tenofibroblasts through activation of prostaglandin E2 production.
Topics: Adolescent; Adult; Autophagy; Celecoxib; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Dinoprostone; Fibroblasts; Humans; Indomethacin; Male; Patellar Ligament; Signal Transduction; Stress, Mechanical | 2015 |
Reduced tonicity stimulates an inflammatory response in nucleus pulposus tissue that can be limited by a COX-2-specific inhibitor.
Topics: Animals; Cattle; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Interleukin-6; Intervertebral Disc; Stress, Mechanical; Tissue Culture Techniques | 2015 |
Biocompatibility and intradiscal application of a thermoreversible celecoxib-loaded poly-N-isopropylacrylamide MgFe-layered double hydroxide hydrogel in a canine model.
Topics: Acrylic Resins; Animals; Biocompatible Materials; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Delayed-Action Preparations; Dinoprostone; Disease Models, Animal; Dogs; Female; Gene Expression; Humans; Hydrogels; Hydroxides; Immunohistochemistry; Injections, Subcutaneous; Intervertebral Disc; Intervertebral Disc Degeneration; Mice, Inbred BALB C; Reverse Transcriptase Polymerase Chain Reaction; Rheology; Temperature | 2015 |
The effect and mechanism of celecoxib in hypoxia-induced survivin up-regulation in HUVECs.
Topics: Celecoxib; Cell Hypoxia; Cell Proliferation; Cobalt; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Gene Expression Regulation; Genistein; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inhibitor of Apoptosis Proteins; Survivin; Up-Regulation | 2015 |
Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Caspase 3; Celecoxib; Cell Line, Tumor; Cisplatin; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Stomach Neoplasms; Tumor Suppressor Protein p53 | 2015 |
Dynamic weight bearing as a non-reflexive method for the measurement of abdominal pain in mice.
Topics: Abdominal Pain; Aniline Compounds; Animals; Behavior, Animal; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Furans; Inflammation; Mice; Pain Measurement; Pelvic Pain; Peritoneal Lavage; Peritonitis; Sodium Channel Blockers; Weight-Bearing; Zymosan | 2016 |
Role of COX-2-derived PGE2 on vascular stiffness and function in hypertension.
Topics: Animals; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide; Dinoprostone; Dose-Response Relationship, Drug; Humans; Hypertension; Male; Mice; Rats; Rats, Inbred SHR; Rats, Wistar; Receptors, Prostaglandin E, EP1 Subtype; Structure-Activity Relationship; Vascular Stiffness | 2016 |
Limited efficacy of COX-2 inhibitors on nerve growth factor and metalloproteinases expressions in human synovial fibroblasts.
Topics: Blotting, Western; Celecoxib; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Humans; Metalloproteases; Multivariate Analysis; Nerve Growth Factor; Real-Time Polymerase Chain Reaction; Synovial Membrane | 2016 |
Opposing roles of LTB4 and PGE2 in regulating the inflammasome-dependent scorpion venom-induced mortality.
Topics: Animals; Arachidonate 5-Lipoxygenase; Blotting, Western; Carrier Proteins; Celecoxib; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase Inhibitors; Dinoprostone; In Vitro Techniques; Indoles; Indomethacin; Inflammasomes; Interleukin-1beta; Leukotriene B4; Lipoxygenase Inhibitors; Macrophages; Macrophages, Peritoneal; Mice; Mice, Knockout; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Phosphoproteins; Prostaglandin Antagonists; Receptors, Prostaglandin E, EP2 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Reverse Transcriptase Polymerase Chain Reaction; Scorpion Stings; Scorpion Venoms; Scorpions; Xanthones | 2016 |
Celecoxib, a COX-2 inhibitor, synergistically potentiates the anti-inflammatory activity of docosahexaenoic acid in macrophage cell line.
Topics: Animals; Celecoxib; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Docosahexaenoic Acids; Drug Synergism; Inflammation; Interleukin-6; Lipopolysaccharides; Macrophages; Mice; Nitric Oxide; Nitric Oxide Synthase Type II; Tumor Necrosis Factor-alpha | 2016 |
COX-2 modulates mammary tumor progression in response to collagen density.
Topics: Animals; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Collagen Type I; Collagen Type I, alpha 1 Chain; Cyclooxygenase 2; Dinoprostone; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Macrophages; Mammary Neoplasms, Animal; Mice; Neutrophils; Tumor Microenvironment | 2016 |
Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats.
Topics: Animals; Caco-2 Cells; Cadherins; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-6; Intestinal Absorption; Jejunum; Liver; Liver Cirrhosis; Rats; Rats, Sprague-Dawley; T-Lymphocytes; Tumor Necrosis Factor-alpha; Zonula Occludens-1 Protein | 2016 |
A miR-335/COX-2/PTEN axis regulates the secretory phenotype of senescent cancer-associated fibroblasts.
Topics: Cancer-Associated Fibroblasts; Celecoxib; Cell Movement; Cellular Senescence; Coculture Techniques; Cyclooxygenase 2; Dinoprostone; Humans; MicroRNAs; Phenotype; PTEN Phosphohydrolase; Signal Transduction; Up-Regulation | 2016 |
Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Body Weight; Catechin; CD3 Complex; Celecoxib; Colitis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Combinations; Eating; Gene Expression Regulation; Hydroxyurea; Leukotriene B4; Lipid Peroxidation; Lipoxygenase Inhibitors; Male; Neutrophil Infiltration; Rats; Rats, Sprague-Dawley; Thromboxane B2; Tumor Necrosis Factor-alpha | 2016 |
Novel celecoxib analogues inhibit glial production of prostaglandin E2, nitric oxide, and oxygen radicals reverting the neuroinflammatory responses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide.
Topics: Animals; Astrocytes; Celecoxib; Cell Line; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; Inflammation; Lipopolysaccharides; Mice; Microglia; Neurodegenerative Diseases; Neuroglia; Nitric Oxide; Nitric Oxide Synthase Type II; Prion Proteins; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2016 |
Synthesis and Evaluation of Anti-inflammatory N-Substituted 3,5-Bis(2-(trifluoromethyl)benzylidene)piperidin-4-ones.
Topics: Animals; Anti-Inflammatory Agents; Bone Marrow Cells; Carrageenan; Celecoxib; Cell Survival; Dinoprostone; Disease Models, Animal; Edema; Enzyme-Linked Immunosorbent Assay; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Macrophages; Mice; Nitric Oxide; Piperidones; Rats; RAW 264.7 Cells; Structure-Activity Relationship; Tissue Distribution; Tumor Necrosis Factor-alpha | 2017 |
Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea.
Topics: Animals; Celecoxib; Cell Polarity; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Hypoxia; Immunity; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Neoplasm Invasiveness; RAW 264.7 Cells; Signal Transduction; Sleep Apnea Syndromes; T-Lymphocytes, Regulatory | 2017 |
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
Topics: Animals; Celecoxib; Cell Movement; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; HEK293 Cells; Humans; Inflammation; Interleukin-2; Male; Membrane Proteins; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Prostatic Neoplasms; Serine Endopeptidases; Sulindac; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Design, synthesis and bioactivities of Celecoxib analogues or derivatives.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Design; Inhibitory Concentration 50; Macrophages, Peritoneal; Male; Protein Binding; Rats; Structure-Activity Relationship | 2017 |
Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.
Topics: Animals; CD8-Positive T-Lymphocytes; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Dinoprostone; Female; Gene Expression Regulation, Neoplastic; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Lymphocytes, Tumor-Infiltrating; Mice; Ovarian Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Erythrocyte membrane-encapsulated celecoxib improves the cognitive decline of Alzheimer's disease by concurrently inducing neurogenesis and reducing apoptosis in APP/PS1 transgenic mice.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Apoptosis Regulatory Proteins; beta-Arrestin 1; Brain; Celecoxib; Cell Line, Tumor; Cell Movement; Cognitive Dysfunction; Dinoprostone; Erythrocyte Membrane; HEK293 Cells; Humans; Liposomes; Mice, Transgenic; Mitochondrial Proteins; Models, Biological; Neural Stem Cells; Neurogenesis; Neurons; Phospholipids; Presenilin-1; Prostaglandin D2; Rats, Wistar; Superoxide Dismutase; Tissue Distribution; Up-Regulation | 2017 |
Central mediators of the zymosan-induced febrile response.
Topics: Animals; Body Temperature; Celecoxib; Dinoprostone; Fever; Indomethacin; Infusions, Intraventricular; Injections, Intra-Articular; Injections, Intraperitoneal; Male; Oligopeptides; Peptide Fragments; Piperidines; Rats; Somatostatin; Tropanes; Zymosan | 2017 |
Impairment of the chondrogenic phase of endochondral ossification in vivo by inhibition of cyclooxygenase-2.
Topics: Administration, Oral; Animals; Bone and Bones; Cartilage; Celecoxib; Cell Differentiation; Chondrocytes; Chondrogenesis; Cyclooxygenase 2 Inhibitors; Dinoprostone; Fracture Healing; Gene Expression; Osteogenesis; Rabbits; X-Ray Microtomography | 2017 |
Mori Folium water extract alleviates articular cartilage damages and inflammatory responses in monosodium iodoacetate‑induced osteoarthritis rats.
Topics: Animals; Cartilage, Articular; Celecoxib; Cytokines; Dinoprostone; Disease Models, Animal; Down-Regulation; Interleukin-1beta; Interleukin-6; Iodoacetates; Knee Joint; Male; Matrix Metalloproteinase 13; Morus; Nitric Oxide; Osteoarthritis; Plant Extracts; Plant Leaves; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 2017 |
L161982 alleviates collagen-induced arthritis in mice by increasing Treg cells and down-regulating Interleukin-17 and monocyte-chemoattractant protein-1 levels.
Topics: Animals; Ankle Joint; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Cell Differentiation; Cell Proliferation; Chemokine CCL2; Collagen Type II; Cyclooxygenase 2 Inhibitors; Dinoprostone; Down-Regulation; Female; Humans; Injections, Intraperitoneal; Interleukin-17; Mice; Mice, Inbred DBA; Receptors, Prostaglandin E, EP4 Subtype; Severity of Illness Index; Signal Transduction; T-Lymphocytes, Regulatory; Th17 Cells; Thiophenes; Triazoles | 2017 |
Preconditioning of murine mesenchymal stem cells synergistically enhanced immunomodulation and osteogenesis.
Topics: Alkaline Phosphatase; Animals; Arginase; Celecoxib; Cell Differentiation; Coculture Techniques; Cyclooxygenase 2; Dinoprostone; Gene Expression; Immunomodulation; Interferon-gamma; Interleukin 1 Receptor Antagonist Protein; Lectins, C-Type; Lipopolysaccharides; Macrophages; Male; Mannose Receptor; Mannose-Binding Lectins; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Osteogenesis; Receptors, Cell Surface; Tumor Necrosis Factor-alpha | 2017 |
Effect of COX-2 inhibition on tendon-to-bone healing and PGE2 concentration after anterior cruciate ligament reconstruction.
Topics: Animals; Anterior Cruciate Ligament; Anti-Inflammatory Agents; Bone and Bones; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Osseointegration; Rabbits; Synovial Fluid; Tendons | 2018 |
Cyclooxygenase-2 expression is induced by celecoxib treatment in lung cancer cells and is transferred to neighbor cells via exosomes.
Topics: Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytoplasm; Dinoprostone; Exosomes; Humans; Lung Neoplasms; Protein Transport; Vascular Endothelial Growth Factor A | 2018 |
Celecoxib Does Not Protect against Fibrosis and Inflammation in a Carbon Tetrachloride-Induced Model of Liver Injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbon Tetrachloride; Celecoxib; Collagen; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Enzyme Inhibitors; Epoxide Hydrolases; Liver Cirrhosis; Male; Mice; Phenylurea Compounds; Piperidines | 2018 |
COX-2/EP2-EP4/β-catenin signaling regulates patulin-induced intestinal cell proliferation and inflammation.
Topics: Animals; beta Catenin; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Enteritis; Epithelial Cells; Glycoproteins; Intestines; Male; Oncogene Protein v-akt; Patulin; Plant Proteins; Rats; Rats, Wistar; Receptors, Prostaglandin E, EP2 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Signal Transduction | 2018 |
Contribution of synovial macrophages to rat advanced osteoarthritis pain resistant to cyclooxygenase inhibitors.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Dinoprostone; Disease Models, Animal; Flow Cytometry; Hand Strength; Iodoacetic Acid; Macrophages; Male; Nerve Growth Factor; Nitric Oxide Synthase Type I; Osteoarthritis, Knee; Pain; Pain Measurement; Rats; Rats, Sprague-Dawley; RNA, Messenger; Synovial Fluid; Weight-Bearing | 2019 |
COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis.
Topics: Animals; Carcinogenesis; Celecoxib; Cell Transformation, Neoplastic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Fibroblasts; Humans; Male; Mice; Nuclear Receptor Subfamily 4, Group A, Member 1; Prolactin; Prostatic Neoplasms; Retinoid X Receptors; Signal Transduction; Stromal Cells; Up-Regulation | 2019 |
Lack of Small Intestinal Dysbiosis Following Long-Term Selective Inhibition of Cyclooxygenase-2 by Rofecoxib in the Rat.
Topics: Animals; Bacteria; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dysbiosis; Gastric Mucosa; Gastrointestinal Microbiome; Intestine, Small; Lactones; Male; Microbial Sensitivity Tests; Rats, Wistar; Sulfones; Time Factors | 2019 |
The Expressions of Dickkopf-Related Protein 1 and Frizzled-Related Protein Are Negatively Correlated to Local Inflammation and Osteoarthritis Severity.
Topics: Celecoxib; Cross-Sectional Studies; Dinoprostone; Humans; Inflammation; Intracellular Signaling Peptides and Proteins; Osteoarthritis, Knee | 2021 |
Parainfluenza virus infection enhances NSAIDs-induced inhibition of PGE2 generation and COX-2 expression in human airway epithelial cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Line; Cyclooxygenase 2; Dinoprostone; Epithelial Cells; Humans; Paramyxoviridae Infections; Real-Time Polymerase Chain Reaction | 2019 |
Olive-Derived Hydroxytyrosol Shows Anti-inflammatory Effect without Gastric Damage in Rats.
Topics: Animals; Aspirin; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Edema; Gastric Mucosa; Indomethacin; Male; Olea; Phenylethyl Alcohol; Rats, Sprague-Dawley; Stomach; Stomach Ulcer | 2019 |
Inhibition of COX-2 alleviates lumbar spinal stenosis-induced chronic mechanical allodynia in rats.
Topics: Animals; Cauda Equina; Celecoxib; Chronic Pain; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Dinoprostone; Hyperalgesia; Lumbar Vertebrae; Macrophages; Male; Neuralgia; Pyrroles; Rats, Sprague-Dawley; Spinal Stenosis | 2019 |
Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer.
Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cisplatin; Cyclooxygenase 2; Dinoprostone; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Receptors, Prostaglandin E, EP4 Subtype; Signal Transduction; Stomach Neoplasms; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro.
Topics: Antineoplastic Agents; Apoptosis; Biotinylation; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dendrimers; Dinoprostone; Fibroblasts; Glioblastoma; Humans; Keratinocytes; Leucine; Necrosis; PPAR gamma; Tumor Suppressor Protein p53 | 2019 |
Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-κB Pathway.
Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Mice, Nude; Neoplasm Grading; Neoplasm Invasiveness; NF-kappa B; Nitriles; Ovarian Neoplasms; Phosphorylation; Receptors, Prostaglandin E, EP2 Subtype; Signal Transduction; Sulfones; Transplantation, Heterologous; Xanthones | 2019 |
Impacts of a Specific Cyclooxygenase-2 Inhibitor on Pressure Overload-Induced Myocardial Hypertrophy in Rats.
Topics: Animals; C-Reactive Protein; Cardiomegaly; Celecoxib; Cyclooxygenase 2 Inhibitors; Diet; Dinoprostone; Disease Models, Animal; Drug Administration Schedule; Heart; Male; Organ Size; Random Allocation; Rats, Sprague-Dawley; Receptors, Transforming Growth Factor beta; Smad1 Protein; Smad2 Protein; Smad3 Protein; Tumor Necrosis Factor-alpha; Uric Acid | 2019 |
Sex Differences Revealed in a Mouse CFA Inflammation Model with Macrophage Targeted Nanotheranostics.
Topics: Adjuvants, Immunologic; Administration, Intravenous; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Drug Delivery Systems; Feasibility Studies; Female; Freund's Adjuvant; Inflammation; Macrophages; Male; Mice; Nanomedicine; Pain; Sex Characteristics; Up-Regulation | 2020 |
Quercetin Downregulates Cyclooxygenase-2 Expression and HIF-1
Topics: Angiogenesis Inhibitors; Animals; Aortic Aneurysm, Abdominal; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Models, Animal; Down-Regulation; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Quercetin; Signal Transduction; Vascular Endothelial Growth Factor A | 2020 |
The molecular mechanisms of celecoxib in tumor development.
Topics: Apoptosis; Autophagy; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mitochondria; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction | 2020 |
Design, synthesis and molecular modeling of novel aryl carboximidamides and 3-aryl-1,2,4-oxadiazoles derived from indomethacin as potent anti-inflammatory iNOS/PGE2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Dinoprostone; Dose-Response Relationship, Drug; Edema; Enzyme Inhibitors; Humans; Indomethacin; Lipopolysaccharides; Male; Mice; Molecular Docking Simulation; Molecular Structure; Nitric Oxide; Nitric Oxide Synthase Type II; Oxadiazoles; Oximes; Rats; RAW 264.7 Cells | 2020 |
Celecoxib and Afatinib synergistic enhance radiotherapy sensitivity on human non-small cell lung cancer A549 cells.
Topics: A549 Cells; Afatinib; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Survival; Cyclooxygenase 2; Dinoprostone; Drug Synergism; ErbB Receptors; Humans; Lung Neoplasms; Radiation Tolerance | 2021 |
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway | 2021 |
Intracellular AGR2 transduces PGE2 stimuli to promote epithelial-mesenchymal transition and metastasis of colorectal cancer.
Topics: Animals; Celecoxib; Cell Line; Cell Line, Tumor; Colorectal Neoplasms; Dinoprostone; Epithelial-Mesenchymal Transition; HCT116 Cells; HEK293 Cells; Histones; HT29 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mucoproteins; Oncogene Proteins; Oncogenes; Phosphatidylinositol 3-Kinases; Receptors, Peptide; Signal Transduction; Tumor Microenvironment | 2021 |
Physiologically relevant aspirin concentrations trigger immunostimulatory cytokine production by human leukocytes.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2; Cytokines; Dinoprostone; Gene Expression Regulation; Humans; Indomethacin; Inflammation; Interleukin-10; Interleukin-1beta; Interleukin-6; Leukocytes; Male; Middle Aged; Toll-Like Receptors; Young Adult | 2021 |
PACER lncRNA regulates COX-2 expression in lung cancer cells.
Topics: Arachidonic Acid; Celecoxib; Cyclooxygenase 2; Cytokines; Dinoprostone; Humans; Inflammation; Lung; Lung Neoplasms; NF-kappa B; RNA, Long Noncoding; RNA, Small Interfering; Transcription Factor AP-1 | 2022 |
Short-term celecoxib (celebrex) adjuvant therapy: a clinical trial study on COVID-19 patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; COVID-19 Drug Treatment; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Pyrazoles; SARS-CoV-2; Sulfonamides | 2022 |
Inhibition of PGE2 in Subchondral Bone Attenuates Osteoarthritis.
Topics: Animals; Capsaicin; Cartilage, Articular; Celecoxib; Dinoprostone; Humans; Mice; Mice, Knockout; Osteoarthritis; Pain | 2022 |
Cyclooxygenase-2 activates EGFR-ERK1/2 pathway via PGE2-mediated ADAM-17 signaling in testosterone-induced benign prostatic hyperplasia.
Topics: ADAM17 Protein; Animals; Celecoxib; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Hyperplasia; Inflammation; Male; MAP Kinase Signaling System; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Rats, Wistar; Testosterone; Transforming Growth Factor alpha | 2023 |
Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer.
Topics: Cadherins; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Dinoprostone; Female; Glycogen Synthase Kinase 3 beta; Humans; Signal Transduction; Triple Negative Breast Neoplasms | 2023 |
Low-dose celecoxib-loaded PCL fibers reverse intervertebral disc degeneration by up-regulating CHSY3 expression.
Topics: Animals; Celecoxib; Dinoprostone; Disease Models, Animal; Intervertebral Disc Degeneration; Mice; Rabbits | 2023 |
2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Celecoxib; Dinoprostone; Gastrointestinal Microbiome; Liver Neoplasms; Mice; T-Cell Exhaustion; Tumor Microenvironment | 2023 |
Exploring COX-2 inhibitors in tuberculosis: A whole-blood model approach for immune response and adjunt therapy evaluation.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Humans; Immunity; Inflammation; Leukotriene B4; Mycobacterium tuberculosis; Tuberculosis; Tumor Necrosis Factor-alpha | 2023 |